0001558370-23-014884.txt : 20230814 0001558370-23-014884.hdr.sgml : 20230814 20230814164020 ACCESSION NUMBER: 0001558370-23-014884 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Annovis Bio, Inc. CENTRAL INDEX KEY: 0001477845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262540421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39202 FILM NUMBER: 231171304 BUSINESS ADDRESS: STREET 1: 1055 WESTLAKES DRIVE, SUITE 300 CITY: BERWYN STATE: PA ZIP: 19312 BUSINESS PHONE: 610-727-3913 MAIL ADDRESS: STREET 1: 1055 WESTLAKES DRIVE, SUITE 300 CITY: BERWYN STATE: PA ZIP: 19312 FORMER COMPANY: FORMER CONFORMED NAME: QR Pharma, Inc. DATE OF NAME CHANGE: 20091202 10-Q 1 anvs-20230630x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED June 30, 2023


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER 001-39202

Annovis Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware		26-2540421
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1055 Westlakes Drive, Suite 300

Berwyn, PA 19312

(Address of registrant’s principal executive offices)

(610) 727-3913

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		ANVS		New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No.

The number of outstanding shares of the registrant’s common stock as of August 11, 2023 was: 9,012,273.

Table of Contents

ANNOVIS BIO, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED JUNE 30, 2023

PART I – FINANCIAL INFORMATION		Page


Item 1.	Financial Statements	3

	Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022	3

	Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2023 and 2022 (Unaudited)	4

	Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2023 and 2022 (Unaudited)	5

	Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022 (Unaudited)	6

	Notes to Financial Statements (Unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3.	Quantitative and Qualitative Disclosure About Market Risk	23

Item 4.	Controls and Procedures	24


PART II – OTHER INFORMATION


Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3.	Defaults Upon Senior Securities	25

Item 4.	Mine Safety Disclosures	25

Item 5.	Other Information	25

Item 6.	Exhibits	26

	Signatures	27

Table of Contents

EXPLANATORY NOTE

As disclosed in our Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023 (the “Filing Date” and “Form 10-K”), Annovis Bio, Inc. (“Annovis,” the “Company,” “our,” “us” and “we”) restated (the “Restatement”) our previously issued (i) unaudited condensed balance sheets as of March 31, 2022, June 30, 2022 and September 30, 2022, (ii) unaudited condensed statements of operations and comprehensive loss for the three months ended March 31, 2022, three and six months ended June 30, 2022, and three and nine months ended September 30, 2022, and (iii) unaudited condensed statements of cash flows for the three months ended March 31, 2022, six months ended June 30, 2022 and nine months ended September 30, 2022, in each of the Quarterly Reports on Form 10- Q for the quarterly periods ended March 31, 2022, June 30, 2022 and September 30, 2022

See Note 12 – Restatement of Previously Issued Unaudited Condensed Financial Statements, to the Financial Statements in the Form 10-K for additional information related to the restatement and additional information related to the restatement of the Condensed Financial Statements for the quarter ended June 30, 2022.

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

Annovis Bio, Inc.

Balance Sheets

(unaudited)


	June 30,		December 31,
	2023		2022

Assets
Current assets:
Cash and cash equivalents	$	15,724,629	$	28,377,693
Prepaid expenses and other current assets		7,091,855		7,644,376
Total current assets		22,816,484		36,022,069
Total assets	$	22,816,484	$	36,022,069
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,172,877	$	3,961,254
Accrued expenses		900,972		3,737,285
Total current liabilities		2,073,849		7,698,539
Total liabilities		2,073,849		7,698,539
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding		—		—
Common stock - $0.0001 par value, 70,000,000 and 35,000,000shares authorized and 9,012,273 and 8,163,923 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively		902		816
Additional paid-in capital		94,070,810		82,377,488
Accumulated deficit		(73,329,077)		(54,054,774)
Total stockholders’ equity		20,742,635		28,323,530
Total liabilities and stockholders’ equity	$	22,816,484	$	36,022,069

See accompanying notes to financial statements.

Table of Contents

Annovis Bio, Inc.

Statements of Operations and Comprehensive Loss

(unaudited)


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Operating expenses:
Research and development	$	8,262,167	$	4,033,963	$	16,048,223	$	6,183,604
General and administrative		1,497,533		1,938,447		3,681,193		5,042,518
Total operating expenses		9,759,700		5,972,410		19,729,416		11,226,122
Operating loss		(9,759,700)		(5,972,410)		(19,729,416)		(11,226,122)
Other income:
Interest income, net		222,578		36,024		455,113		55,673
Total other income		222,578		36,024		455,113		55,673
Loss before income taxes		(9,537,122)		(5,936,386)		(19,274,303)		(11,170,449)
Income tax expense (benefit)		—		—		—		—
Net loss	$	(9,537,122)	$	(5,936,386)	$	(19,274,303)	$	(11,170,449)
Basic and diluted loss per common share	$	(1.07)	$	(0.73)	$	(2.25)	$	(1.37)
Weighted average number of common shares outstanding, basic and diluted		8,951,309		8,163,923		8,575,239		8,160,702

See accompanying notes to financial statements.

Table of Contents

Annovis Bio, Inc.

Statements of Changes in Stockholders’ Equity

(unaudited)


				Additional				Total
	Common Stock			Paid-In		Accumulated		Stockholders'
	Shares	Amount		Capital		Deficit		Equity
Three and Six Months Ended June 30, 2023
Balance, December 31, 2022	8,163,923	$	816	$	82,377,488	$	(54,054,774)	$	28,323,530
Exercise of stock options	52,755		6		7,380		—		7,386
Stock-based compensation expense	—		—		1,542,338		—		1,542,338
Net and comprehensive loss	—		—		—		(9,737,181)		(9,737,181)
Balance, March 31, 2023	8,216,678	$	822	$	83,927,206	$	(63,791,955)	$	20,136,073
Issuance of common stock, net of issuance costs	788,453		79		8,571,112		—		8,571,191
Exercise of stock options	7,142		1		999		—		1,000
Stock-based compensation expense	—		—		1,571,493		—		1,571,493
Net and comprehensive loss	—		—		—		(9,537,122)		(9,537,122)
Balance, June 30, 2023	9,012,273	$	902	$	94,070,810	$	(73,329,077)	$	20,742,635


Three and Six Months Ended June 30, 2022
Balance, December 31, 2021	8,100,570	$	810	$	73,220,361	$	(28,726,207)	$	44,494,964
Exercise of stock options	63,353		6		4,607		—		4,613
Stock-based compensation expense	—		—		3,434,944		—		3,434,944
Net and comprehensive loss	—		—		—		(5,234,063)		(5,234,063)
Balance, March 31, 2022	8,163,923	$	816	$	76,659,912	$	(33,960,270)	$	42,700,458
Stock-based compensation expense	—		—		1,903,761		—		1,903,761
Net and comprehensive loss	—		—		—		(5,936,386)		(5,936,386)
Balance, June 30, 2022	8,163,923	$	816	$	78,563,673	$	(39,896,656)	$	38,667,833

See accompanying notes to financial statements.

Table of Contents

Annovis Bio, Inc.

Statements of Cash Flows

(unaudited)


	Six Months Ended June 30,
	2023		2022
Cash flows from operating activities:
Net loss	$	(19,274,303)	$	(11,170,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		3,113,831		5,338,705
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		552,521		(3,677,503)
Accounts payable		(2,788,377)		213,767
Accrued expenses		(2,836,313)		(420,896)
Net cash used in operating activities		(21,232,641)		(9,716,376)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs		8,571,191		—
Proceeds from exercise of stock options		8,386		4,613
Net cash provided by financing activities		8,579,577		4,613
Net (decrease) increase in cash and cash equivalents		(12,653,064)		(9,711,763)
Cash and cash equivalents, beginning of year		28,377,693		45,686,014
Cash and cash equivalents, end of period	$	15,724,629	$	35,974,251

See accompanying notes to financial statements.

Table of Contents

Annovis Bio, Inc.

Notes to Financial Statements

(Unaudited)

(1) Nature of Business, Going Concern and Management’s Plan

Annovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company’s lead product candidate, buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. The Company has shown in its clinical and pre-clinical studies that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.

Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.

The Company’s primary source of capital has been the issuance of equity securities. The Company’s common stock trades on the New York Stock Exchange under the ticker symbol “ANVS”

At present, the Company lacks sufficient capital on hand to fund its operations for the next 12 months and will need to raise additional capital to ensure its continuity of operations. The Company believes that its current cash and cash equivalents will be sufficient to fund its operations into the first quarter of 2024, including its ongoing Phase 2/3 AD Trial and its ongoing Phase 3 PD Trial. The Company plans to raise additional capital to complete the development and commercialization of its product candidates through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives; however, there can be no assurance that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. The failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on the Company’s business, results of operations, and financial condition. Accordingly, management has concluded that substantial doubt exists with respect to the Company's ability to continue as a going concern for one year after the date that these financial statements are issued.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

The accompanying interim financial statements of Annovis Bio, Inc. should be read in conjunction with the audited financial statements and notes thereto included in the Company’s 2022 Annual Report on Form 10-K filed with

Table of Contents

the Securities and Exchange Commission (the “SEC”) on March 31, 2023. In the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, the Company restated (i) unaudited condensed balance sheets as of March 31, 2022, June 30, 2022 and September 30, 2022, (ii) unaudited condensed statements of operations and comprehensive loss for the three months ended March 31, 2022, three and six months ended June 30, 2022, and three and nine months ended September 30, 2022, and (iii) unaudited condensed statements of cash flows for the three months ended March 31, 2022, six months ended June 30, 2022 and nine months ended September 30, 2022, in each of the Quarterly Reports on Form 10- Q for the quarterly periods ended March 31, 2022, June 30, 2022 and September 30, 2022 The restatement resulted from the Company's prior accounting for payments for research and development expenses and recognition of expenses. Accordingly, certain amounts for the three and six months ended June 30, 2022 presented herein reflect the restated amounts.

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at June 30, 2023, its results of operations for the three and six months ended June 30, 2023 and 2022 and its cash flows for the six month periods ended June 30, 2023 and 2022. The interim results of operations are not necessarily indicative of the results to be expected for a full year or any future period. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the SEC. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include stock-based compensation expense, and prepaid expenses and accrued liabilities that are measured based on progress toward completion of research and development projects. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect.

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $ 250,000. Any loss incurred or a lack of access to such funds, could have a significant adverse effect on the Company’s financial condition, results of operations and cash flows.

Table of Contents

(e) Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.

(g) Research and Development

Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company’s contracts with its vendors, and are realized in the ordinary course of business

(h) Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the fair value of the award and is generally recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company also has options outstanding with a performance-based vesting conditions, for which the Company recognizes expense based on the estimated probability of achievement of the performance metrics over the contractual term of the option. Forfeitures are recognized in compensation expense in the period when they occur.

The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(i) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2023 and December 31, 2022, the Company has recorded a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition

Table of Contents

and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at June 30, 2023 or December 31, 2022.

(j) Recent Accounting Pronouncements

There are no recent accounting pronouncements that would have a significant impact on the Company’s financial statements.

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022:


			Fair Value Measurement at
			June 30, 2023
	Carrying Value		Level 1		Level 2		Level 3
Cash equivalents	$	15,655,971	$	15,655,971	$	—	$	—


			Fair Value Measurement at
			December 31, 2022
	Carrying Value		Level 1		Level 2		Level 3
Cash equivalents	$	26,001,934	$	26,001,934	$	—	$	—

Table of Contents

(4) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:


	June 30,		December 31,
	2023		2022
Prepaid expenses	$	65,269	$	67,532
Prepaid clinical trial expenses		6,895,959		7,528,250
Prepaid insurance		104,605		37,356
Security deposits and other		26,022		11,238
	$	7,091,855	$	7,644,376

(5) Accrued Expenses

Accrued expenses consisted of the following:


	June 30,		December 31,
	2023		2022
Payroll and related benefits	$	260,287	$	556,827
Accrued professional and clinical fees		640,685		3,180,458
	$	900,972	$	3,737,285

(6) Commitments and Contingencies

(a) Research & Development

The Company has entered into contracts with contract research organizations (CROs) and contract manufacturers (CMOs) related the Company's clinical trials. The contracts require upfront payments, milestone payments, and pass through cost reimbursement, to be made. While the contracts are cancellable with (written) notice, the Company is obligated for payments for services rendered through the termination date of the project with the CRO/CMO.

(b) Leases

The Company leases its office facilities under a month-to-month operating lease. Total rental expense was $17,712 and $16,081 for the three months ended June 30, 2023 and 2022, respectively, and $35,273 and $33,358 for the six months ended June 30, 2023 and 2022, respectively

The Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreements were approximately $1,274,500 at June 30, 2023.

(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

Table of Contents

At June 30, 2023, the Company did not have any pending legal actions.

(7) Stockholders’ Equity

(a) Overview

The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company’s initial public offering (the “IPO”) and amended on June 15, 2023 to increase the authorized number of shares. Currently, there are authorized of two classes of stock designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 72,000,000, each with a par value of $0.0001 per share. Of these shares, 70,000,000 shall be common stock and 2,000,000 shall be preferred stock.

On March 31, 2023, the “Company, entered into an ATM Equity Offering Sales Agreement SM (the “Sales Agreement”) with BofA Securities, Inc. (“BofA”) and ThinkEquity LLC (“ThinkEquity” and, together with BofA, the “Sales Agents”), as sales agents, pursuant to which the Company may offer and sell, from time to time through the Sales Agents, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50.0 million.

On April 4, 2023, the Company delivered written notice to BofA and ThinkEquity to terminate the Sales Agreement, effective April 9, 2023, pursuant to Section 9(a) of the Sales Agreement. The Company is not subject to any termination penalties related to the termination of the Sales Agreement.

Prior to termination of the Sales Agreement, the Company sold 704,000 shares of Common Stock pursuant to the Sales Agreement at a price of $10.88 per share, for gross proceeds of $7,659,520 before commissions. As a result of the termination of the Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the Sales Agreement.

In addition, on April 7, 2023, the Company sold 84,453 shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $12.61 per share, for aggregate proceeds of $ 1.06 million.

(b) Common Stock

1. Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.

2. Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

3. Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

Table of Contents

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of June 30, 2023 or December 31, 2022.

(d) Warrants

In conjunction with the closing of the Company’s IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which was 125% of the initial public offering price. The warrants have a five-year term and were exercisable as of January 29, 2021 and have been classified by the Company as a component of stockholders’ equity. As of June 30, 2023 and December 31, 2022, 2,400 of the warrants were outstanding. No warrants were exercised during the three or six months ended June 30, 2023 or 2022.

(8) Stock-Based Compensation

The Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective on January 31, 2020, succeeding the Company’s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 to 2,000,000. As of June 30, 2023, 281,169 shares were available for future grants.

Stock-based compensation expense was as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
General and administrative	$	644,353	$	1,180,639	$	1,413,455	$	3,425,682
Research and development		927,140		723,122		1,700,376		1,913,023
	$	1,571,493	$	1,903,761	$	3,113,831	$	5,338,705

During the six months ended June 30, 2023, the Company granted options to purchase 111,705 shares of common stock at a weighted-average exercise price of $13.29 per share to employees. Under the grant agreements, 30,000 of the options vested immediately and have a 10-year term. The rest of the options have service based vesting conditions and generally vest in substantially equal quarterly installments over two years and have a 10 year term. The options granted during the six months ended June 30, 2023 were valued using the Black Scholes option pricing model using the following weighted-average assumptions: (i) expected term of 5.6 years; (ii) risk free interest rate of 3.55%; (iii) expected volatility of 128.6%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of options issued by the Company during the three months ended June 30, 2023 was $11.72 per share.

Stock options exercised during the three months ended June 30, 2023 and 2022, were 7,142 and 0, respectively. Stock options exercised during the six months ended June 30, 2023 and 2022, were 59,897 and 70,101, respectively. As of June 30, 2023, there were 1,709,150 options outstanding, of which 1,426,229 were vested and exercisable. As of December 31, 2022, there were 1,657,342 options outstanding, of which 1,310,667 were vested and exercisable.

Table of Contents

(9) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Numerator
Net loss	$	(9,537,122)	$	(5,936,386)	$	(19,274,303)	$	(11,170,449)
Denominator
Weighted-average common shares outstanding, basic and diluted		8,951,309		8,163,923		8,575,239		8,160,702
Net loss per share, basic and diluted	$	(1.07)	$	(0.73)	$	(2.25)	$	(1.37)

The Company reported a net loss for the three and six months ended June 30, 2023 and 2022, therefore, the basic and diluted net loss per share were the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that were excluded from the computation of diluted weighted-average shares outstanding were as follows:


	June 30,
	2023	2022
Stock options	1,709,150	1,627,941
Warrants	2,400	2,400

(10) Income Taxes

The Company’s income tax benefit (expense) was $0 for the three and six months ended June 30, 2023 and 2022. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss (“NOL”) that would have been recognized in the three and six months ended June 30, 2023 and 2022 was offset by changes in the valuation allowance.

Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.

As of June 30, 2023, and December 31, 2022, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.

(11) Restatement of Previously Issued Unaudited Condensed Financial Statements

As disclosed in the Form 10-K filed with the SEC on March 31, 2023, during its preparation of its 2022 audited combined financial statements and notes thereto, the Company concluded that there were material research and development expenses and related balance sheet errors in its previously issued unaudited condensed financial statements for the three and six months ended June 30, 2022, primarily relating to the timing of payments for research and development expenses and recognition of expenses.

Table of Contents

The Company noted the following items were improperly expensed during the three and six months ended June 30, 2022:

● Payments, in the amount of $2,883,977 were improperly recorded in research and development expenses during the three months ended June 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of June 30, 2022. Additionally, $102,232 was expensed during the three months ended June 30, 2022 related to the prior quarter restatements.

These errors, including the errors from the three months ended March 31, 2022, in the accounting for research and development expenses resulted in a cumulative understatement of prepaid assets and other current assets of $3,441,895, as of June 30, 2022, and an overstatement operating expenses and net loss of $2,781,745 and $3,441,895 for the three and six months ended June 30, 2022, respectively. See Note 12 – Restatement of Previously Issued Unaudited Condensed Financial Statements, to the Financial Statements in the Form 10-K for additional information related to the restatements.

In connection with the filing of this Quarterly Report on Form 10-Q, the Company has restated the accompanying interim Condensed Financial Statements for the quarter ended June 30, 2022 to correct for the impact of the misstatements. The applicable notes to the accompanying financial statements have also been corrected to reflect the impact of the restatement. Below, we have presented a reconciliation from the "As Reported" to the "As Restated" amounts for each of our interim Condensed Financial Statements as of and for the three and six months ended June 30, 2022. The amounts "As Reported" are from the "As Reported" amounts as disclosed in Note 12 – Restatement of Previously Issued Unaudited Condensed Financial Statements (Unaudited) in the Form 10-K.


	As of June 30, 2022
	(unaudited)
	As		Restatement		As
	Reported		Impacts		Restated
Assets
Current assets:
Cash and cash equivalents	$	35,974,251	$		$	35,974,251
Prepaid expenses and other current assets		551,072		3,441,895		3,992,967
Deferred clinical materials		—		—		—
Total current assets		36,525,323		3,441,895		39,967,218
Total assets	$	36,525,323	$	3,441,895	$	39,967,218
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	901,841	$		$	901,841
Accrued expenses		397,544				397,544
Total current liabilities		1,299,385		—		1,299,385
Total liabilities	$	1,299,385	$	—	$	1,299,385
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding		—				—
Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively		816				816
Additional paid-in capital		78,563,673				78,563,673
Accumulated deficit		(43,338,551)		3,441,895		(39,896,656)
Total stockholders' equity		35,225,938		3,441,895		38,667,833
Total liabilities and stockholders' equity	$	36,525,323	$	3,441,895	$	39,967,218

Table of Contents


	Three Months Ended June 30, 2022
	As		Restatement		As
	Reported		Impacts		Restated
Operating expenses:
Research and development	$	6,815,708	$	(2,781,745)	$	4,033,963
General and administrative		1,938,447		—		1,938,447
Total operating expenses		8,754,155		(2,781,745)		5,972,410

Operating loss		(8,754,155)		2,781,745		(5,972,410)
Other income:
Interest income		36,024		—		36,024
Grant Income
Total other income		36,024		—		36,024

Loss before income taxes		(8,718,131)		2,781,745		(5,936,386)
Income tax expense (benefit)		—		—		—
Net loss	$	(8,718,131)	$	2,781,745	$	(5,936,386)
Basic and diluted loss per common share	$	(1.07)		—	$	(0.73)
Weighted average number of common shares outstanding, basic and diluted		8,163,923		—		8,163,923


	Six Months Ended June 30, 2022
	As		Restatement		As
	Reported		Impacts		Restated
Operating expenses:
Research and development	$	9,625,499	$	(3,441,895)	$	6,183,604
General and administrative		5,042,518		—		5,042,518
Total operating expenses		14,668,017		(3,441,895)		11,226,122

Operating loss		(14,668,017)		3,441,895		(11,226,122)
Other income:
Interest income		55,673		—		55,673
Grant Income
Total other income		55,673		—		55,673

Loss before income taxes		(14,612,344)		3,441,895		(11,170,449)
Income tax expense (benefit)		—		—		—
Net loss	$	(14,612,344)	$	3,441,895	$	(11,170,449)
Basic and diluted loss per common share	$	(1.79)		—	$	(1.37)
Weighted average number of common shares outstanding, basic and diluted		8,160,702		—		8,160,702

Table of Contents


	Six Months Ended June 30, 2022
	As		Restatement	As
	Reported		Impacts	Restated
Cash flows from operating activities:
Net loss	$	(14,612,344)	3,441,895	$	(11,170,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		5,338,705	—		5,338,705
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(235,608)	(3,441,895)		(3,677,503)
Accounts payable		213,767	—		213,767
Accrued expenses		(420,896)	—		(420,896)
Net cash used in operating activities		(9,716,376)	—		(9,716,376)
Cash flows from financing activities:
Proceeds from exercise of stock options		4,613	—		4,613
Net cash used in financing activities		4,613	—		4,613
Net (decrease) increase in cash and cash equivalents		(9,711,763)	—		(9,711,763)
Cash and cash equivalents, beginning of period		45,686,014	—		45,686,014
Cash and cash equivalents, end of period	$	35,974,251	—	$	35,974,251

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

●

our business strategies;

●

the timing of regulatory submissions;

●

our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;

●

risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;

●

risks related to market acceptance of products;

●

risks associated with our reliance on third-party organizations;

●

our competitive position;

●

assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates;

●

our intellectual property position and our ability to maintain and protect our intellectual property rights;

●

our results of operations, financial condition, liquidity, prospects, and growth strategies;

●

our cash needs and financing plans;

●

the industry in which we operate; and

●

the trends that may affect the industry or us.

You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022 for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Those factors are updated, as applicable, in “Factors that May Affect Future Results” below. As a result of the risks, uncertainties and assumptions described above and elsewhere, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the

Table of Contents

significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with: (i) the interim financial statements and related notes thereto which are included in this Quarterly Report on Form 10-Q; and (ii) our annual financial statements for the year ended December 31, 2022 which are included in our Annual Report on Form 10-K for the year ended December 31, 2022.

Restatement of Previously Issued Consolidated Financial Statements

As disclosed in our Annual Report on Form 10-K filed with the SEC on March 31, 2023, during our preparation of our 2022 audited combined financial statements and notes thereto, we concluded that there were material research and development expenses and related balance sheet errors in its previously issued unaudited condensed financial statements as of and for each of the quarterly and year to date periods ended March 31, 2022, June 30, 2022 and September 30, 2022, primarily relating to the timing of payments for research and development expenses and recognition of expenses.

See Note 12 – Restatement of Previously Issued Unaudited Condensed Financial Statements, to the Financial Statements in the Form 10-K for additional information related to the restatements.

Company Overview

We are a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD and other chronic neurodegenerative diseases. buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins—APP/Aβ (“APP”), tau/phospho-tau (“tau”) and α-Synuclein (“αSYN”)—that are the main causes of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our clinical studies in early AD and early PD patients and pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.

In 2021, we completed two Phase 1/2 clinical studies: one in 14 early AD patients, and one in 54 early PD patients (together, the “AD/PD Trials”). In the AD/PD Trials, early AD patients were defined as those with a Mini Mental State Examination (MMSE) score between 19 and 28 and early PD patients as those patients at Hoehn & Yahr stages 1, 2 or 3. MMSE is a brief screening instrument used to assess cognitive function, with total scores ranging from 0 to 30 and a lower score indicating greater disease severity, while the Hoehn & Yahr scale is a medical assessment used to measure staging of the functional disability associated with PD where a higher stage indicates greater disease severity. In collaboration with the Alzheimer’s Disease Cooperative Study (“ADCS”), we also conducted a trial in 16 early AD patients (the “ADCS Trial”). In the ADCS Trial, early AD patients were defined as those patients with a MMSE score between 19 and 28. All three clinical trials were double-blind, placebo-controlled studies. We designed the studies by applying our understanding of the underlying neurodegenerative disease states, and measured efficacy as well as both target and pathway engagement in the spinal fluid of patients to determine whether patients improvement following treatment correlated with the CSF biomarkers. In addition to meeting their primary endpoints of safety and tolerability and secondary endpoint of pharmacokinetics, our AD/PD Trials met exploratory endpoints of measures of biomarkers and improvements in cognition in AD patients, and in function in PD patients. We believe that the AD/PD Trials

Table of Contents

represent the first double-blind placebo-controlled studies that showed improvements in AD patients, as measured by ADAS-Cog, and in PD patients, as measured by UPDRS. Following completion of the AD/PD Trials, we submitted our data to the U.S. Food and Drug Administration (“FDA”) and requested direction to further pursue the development of buntanetap in early PD patients. With the FDA’s guidance, we initiated a Phase 3 study in early PD patients in August 2022 (our “Phase 3 PD Study”). In the Phase 3 PD Study, early PD patients were defined as those at Hoehn & Yahr stages 1, 2 or 3, and OFF times of less than two hours per day. OFF time refers to when PD motor and/or non-motor symptoms occur between medication doses. We also submitted a proposed protocol for the treatment of moderate AD to the FDA, and after receiving permission to proceed, we initiated a Phase 2/3 study in mild to moderate AD patients in February 2023 (our “Phase 2/3 AD Study”). In the Phase 2/3 AD Study, mild to moderate AD patients were defined as those with a MMSE score between 14 and 24. At the completion of the ADCS Trial, the data showed that buntanetap is a translational inhibitor in humans just like in animals, and we further observed that there was statistical improvement in cognition in early AD patients, just like in the AD/PD Trials.

Our Phase 3 PD Study and Phase 2/3 AD Study each have built in interim analyses. Our Phase 3 PD Study incorporated an interim analysis at two months, the results of which were disclosed on March 31, 2023. The pre-planned interim analysis was conducted by our data analytics provider based on 132 patients from all cohorts collectively for which baseline and two-month data was available. As the interim analysis was conducted at two months of the six-month endpoint and only on 132 patients, it may not be indicative of the results at six months for the full patient population because as the trial progresses, clinical outcomes may materially change as patient enrollment continues and more patient data become available, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Based on the results of the interim analysis, we proceeded with the Phase 3 PD Study as planned in accordance with the previously established protocol. We remain blinded to the Phase 3 PD Study and we do not have safety or efficacy data from the trial. A separate safety interim analysis is in progress and we expect that interim analysis to be released in the second quarter of 2023. We intend to disclose the results of an interim analysis for our Phase 2/3 AD Study in Fall 2023. We plan to consult with the FDA following completion of these interim analyses, to obtain feedback on our ongoing and planned AD and PD studies, including conducting an open label extension study following the completion of the initial trials. Using the data from the Phase 3 PD Study interim analysis, we intend to design an 18-month long disease-modifying Phase 3 study in the same early PD patients. In addition, we intend to conduct a short 6-month study in advanced PD patients during the second half of the 18-month disease modifying Phase 3 study, at which time we will define the advanced PD patient population for the purposes of such study. Similarly, using the data from the Phase 2/3 AD Study interim analysis, we intend to design an 18-month disease modifying Phase 3 study in the same early AD patient population. In addition, we intend to conduct a short 6-month study in advanced AD patients during the second half of the 18-month disease modifying Phase 3 study, at which time we will define the advanced AD patient population for the purposes of such study. We expect both the ongoing Phase 3 PD Study and the Phase 2/3 AD Study to be completed by the end of 2023, and we intend to announce the data from the final analyses in the first quarter of 2024.

By the end of 2026, our goal is to have conducted the required pivotal studies for buntanetap to be able to file two new drug applications (“NDAs”) with the FDA.

We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein, and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD as well as body and brain function associated with PD. Based on pre-clinical and clinical data collected to date, we believe that buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling buntanetap to be the only drug to improve cognition in AD and motor function in PD. The industry has encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or αSYN, indicating that doing so does not change the course of neurodegeneration. Our goal is to develop a disease modifying drug (“DMD”) for patients with neurodegeneration by leveraging our clinical and pre-clinical data to inhibit the three most relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and accordingly these diseases present two unmet needs of the aging population and two potentially large U.S. markets if a DMD is developed and approved.

Table of Contents

We have never been profitable and have incurred net losses since inception. Our accumulated deficit at June 30, 2023 was $73,329 thousand. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.

Results of Operations

Operating expenses and other income were comprised of the following:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022

	(in thousands)				(in thousands)
Operating expenses:
Research and development	$	8,262.2	$	4,034.0	$	16,048.2	$	6,183.6
General and administrative	$	1,497.5	$	1,938.4	$	3,681.2	$	5,042.5
Other income:
Interest income	$	222.6	$	36.0	$	455.1	$	55.7

Three Months Ended June 30, 2023 and 2022

Research and Development Expenses

Research and development expenses increased by $4,228.2 thousand for the three months ended June 30, 2023 compared to the prior year period. The increase was primarily the result of an increase of $4,167.5 thousand in clinical expenses related to our Phase 3 study in early PD patients, Phase 2/3 in AD patients, an increase of $204.0 thousand in stock-based compensation expense, partially offset by a decrease of $143.3 thousand in various other expenses. We expect research and development expenses in 2023 will be higher than the prior year as we continue our Phase 3 study in early PD patients and our Phase 2/3 study in moderate AD patients.

General and Administrative Expenses

General and administrative expenses decreased by $441 thousand for the three months ended June 30, 2023 compared to the prior year period. The decrease was primarily the result of a decrease of $536 thousand in stock-based compensation expense, partially offset by an increase of $73.1 and an increase of $21.8 thousand in other expenses, primarily professional fees.

Other Income

Other income increased $187 thousand for the three months ended June 30, 2023 compared to the prior year period. The increase was primarily the result of higher return on investment compared to the prior year period.

Six Months Ended June 30, 2023 and 2022

Research and Development Expenses

Research and development expenses increased by $9,864.6 thousand for the six months ended June 30, 2023 compared to the prior year period. The increase was primarily the result of an increase of $10,437.2 thousand in clinical expenses related to our Phase 3 study in early PD patients, Phase 2/3 in AD patients, offset by decrease of $495.9

Table of Contents

thousand for the cost of materials and an decrease of $212.6 thousand in stock-based compensation expense. We expect research and development expenses in 2023 will be higher than the prior year as we continue our Phase 3 study in early PD patients and our Phase 2/3 study in moderate AD patients.

General and Administrative Expenses

General and administrative expenses decreased by $1,361.3 thousand for the six months ended June 30, 2023 compared to the prior year period. The decrease was primarily the result of a decrease of $2,012.2 thousand in stock-based compensation expense, partially offset by an increase of $654 thousand in professional fees.

Other Income

Other income increased $399.4 thousand for the six months ended June 30, 2023 compared to the prior year period. The increase was primarily the result of higher return on invested funds compared to the prior year period.

Liquidity and Capital Resources

Since our inception in 2008, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of common stock, redeemable convertible preferred stock, and convertible promissory notes and funding from research grants. To date, we have not generated any revenue from the sale of products, and we do not anticipate generating any revenue from the sale of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of June 30, 2023, our principal source of liquidity was our cash and cash equivalents, which totaled $15,724.6 thousand.

Cash Flows

The following table summarizes our cash flows for the respective period:


	Six Months Ended
	June 30,
	2023		2022

	(in thousands)
Statement of Cash Flows Data:
Total net cash provided by (used in):
Operating activities	$	(21,232.6)	$	(9,716.4)
Financing activities		8,579.6		4.6
Net (decrease) in cash and cash equivalents	$	(12,653.0)	$	(9,711.8)

Operating Activities

For the six months ended June 30, 2023, cash used in operations increased $11,723.4 thousand compared to the same period in the prior year. The increase in cash used in operations was primarily the result of an increase in cash paid for clinical trial expenses.

We expect cash used in operating activities to increase in 2023 as compared to 2022 due to an expected increase in our operating losses associated with ongoing development of our product candidates, including clinical trial expenses for our planned Phase 3 trial in early PD patients and a second clinical trial in early AD patients.

Table of Contents

Financing Activities

Cash provided by financing activities during the six months ended June 30, 2023 was due to $8,571.2 thousand in proceeds from the sale of common stock and $8.4 thousand in proceeds from the exercise of stock options.

Funding Requirements

We do not have sufficient capital on hand to fund our operations for the next 12 months and will need to raise additional capital to meet our obligations as they become due. We believe that our current cash and cash equivalents and funding from existing grants will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2024, including our ongoing Phase 2/3 AD Trial and our ongoing Phase 3 PD Trial. We will need to raise substantial additional capital to complete the development and commercialization of our product candidates through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. However, there can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. We have no committed external sources of funds. If we are unable to raise sufficient additional capital or defer sufficient operating expenses, we may be compelled to reduce the scope of our operations.

In order to fund operations and additional clinical trials, we plan to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.

Contractual Obligations and Other Commitments

This item is not required for smaller reporting companies.

Factors that May Affect Future Results

You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022 for a discussion of important factors that may affect our future results.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined by applicable SEC regulations.

Discussion of Critical Accounting Policies and Significant Judgments and Estimates

The preparation of financial statements in conformity with GAAP requires us to use judgment in making certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in our financial statements and accompanying notes. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require difficult, subjective and complex judgments by management in order to make estimates about the effect of matters that are inherently uncertain. During the six month period ended June 30, 2023, there were no significant changes to our critical accounting policies from those described in our annual financial statements for the year ended December 31, 2022, which we included in our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

This item is not required for smaller reporting companies.

Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were not effective, due to the material weakness in our internal control over financial reporting described below, to ensure that the information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Identified Material Weakness

In connection with the audit of our financial statements as of December 31, 2022 and 2021 and for the years ended December 31, 2022 and 2021, we identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness related to the proper classification of research and development expenses, which impacted our previously issued condensed financial statements as of and for the three months ended March 31, 2022, three and six months ended June 30, 2022 and three and nine months ended September 30, 2022.

Remediation Plan

Our management, with the oversight of the Audit Committee of the Board of Directors, has updated our internal processes and controls to strengthen their effectiveness and developed a remediation plan which includes the following actions:

●

Enhance our review procedures over significant contracts with contract manufacturing organizations and contract research organizations;

●

Augment existing staff; and

●

Strengthen the review process.

We will not be able to conclude whether the actions we are taking will fully remediate the material weakness in our internal control over financial reporting until the updated controls have operated for a sufficient period of time and management has concluded, through testing, that such controls are operating effectively. We may also conclude that additional measures may be required to remediate the material weakness in our internal control over financial reporting, which may necessitate further action.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(f) and 15d-15(f) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. except for the initiation of our remediation efforts with respect to the material weakness relating to our internal control over financial reporting described above. We have taken actions to remediate the material weakness, which has resulted and may continue to result in changes in our internal control over financial reporting in periods subsequent to March 31, 2023 as we continue to address this material weakness.

Table of Contents

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.

Item 1A. Risk Factors

This item is not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits


Exhibit Number		Description of Exhibit

3.1		Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to Form 8-K filed February 6, 2020.)

3.2		Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit 3.2 to Form 8-K filed February 6, 2020.)

31.1		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


101.INS		XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Signature	Title	Date

/s/ Maria Maccecchini	President and Chief Executive Officer (principal	August 14, 2023
Maria Maccecchini	executive officer)

/s/ Henry Hagopian	Chief Financial Officer (principal financial and	August 14, 2023
Henry Hagopian	accounting officer)

EX-31.1 2 anvs-20230630xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Maria Maccecchini, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 14, 2023	/s/ Maria Maccecchini
	Maria Maccecchini
	President and Chief Executive Officer

EX-31.2 3 anvs-20230630xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Henry Hagopian III, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 14, 2023	/s/ Henry Hagopian III
	Henry Hagopian III
	Chief Financial Officer

EX-32.1 4 anvs-20230630xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 14, 2023	/s/ Maria Maccecchini
	Maria Maccecchini
	President and Chief Executive Officer

EX-32.2 5 anvs-20230630xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Henry Hagopian III, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: August 14, 2023	/s/ Henry Hagopian III
	Henry Hagopian III
	Chief Financial Officer

EX-101.SCH 6 anvs-20230630.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business, Going Concern and Management's Plan link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business, Going Concern and Management's Plan (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Commitments and Contingencies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Commitments and Contingencies - Employment Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Stockholders' Equity - Overview (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Stockholders' Equity - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 41105 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 anvs-20230630_cal.xml EX-101.CAL EX-101.DEF 8 anvs-20230630_def.xml EX-101.DEF EX-101.LAB 9 anvs-20230630_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Document Information [Line Items] Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Balance Sheets Statement [Table] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits. Prepaid Expense, Security Deposits, and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Assets, Current Total current assets Total current assets Assets Total assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Accrued Liabilities and Interest, and Employee-Related Liabilities, Current Accrued expenses Total accrued expenses Accrued expenses and other current liabilities Liabilities, Current Total current liabilities Total current liabilities Liabilities Total liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 7) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding Common Stock, Value, Issued Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively Common stock - $0.0001 par value, 70,000,000 and 35,000,000 shares authorized and 9,012,273 and 8,163,923 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Number of preferred shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Number of common shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Statements of Operations and Comprehensive Loss Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Total operating expenses Operating Income (Loss) Operating loss Operating loss Nonoperating Income (Expense) [Abstract] Other income: Interest Income (Expense), Nonoperating, Net Interest income, net Interest income Nonoperating Income (Expense) Total other income Total other income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Loss before income taxes Income Tax Expense (Benefit) Income tax expense (benefit) Net Income (Loss) Attributable to Parent Net loss Net loss Net and comprehensive loss Earnings Per Share, Basic Basic loss per common share Net loss per share, basic Earnings Per Share, Diluted Diluted loss per common share Net loss per share, diluted Weighted Average Number of Shares Outstanding, Basic Weighted average number of common shares outstanding, basic Weighted-average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted average number of common shares outstanding, diluted Weighted-average common shares outstanding, diluted Statements of Changes in Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock Additional Paid-In Capital Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Changes in Stockholders' Equity Shares, Issued Balance, shares Balance, shares Stock Issued During Period, Value, New Issues Issuance of common stock, net of issuance costs Stock Issued During Period, Shares, New Issues Issuance of common stock, net of issuance costs, shares Issuance of common stock Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options, shares APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Stock-based compensation expense Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Payment Arrangement, Noncash Expense Stock-based compensation expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of issuance costs Proceeds from Stock Options Exercised Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) increase in cash and cash equivalents Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of period Cash and cash equivalents, beginning of year Nature of Business, Going Concern and Management's Plan Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Nature of Business, Going Concern and Management's Plans Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Prepaid Expenses and Other Current Assets The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block] Prepaid Expenses and Other Current Assets Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Stock-Based Compensation Share-based Payment Arrangement [Text Block] Stock-Based Compensation Net Loss Per Share Earnings Per Share [Text Block] Net Loss Per Share Income Taxes Income Tax Disclosure [Text Block] Income Taxes Restatement of Previously Issued Unaudited Condensed Financial Statements Error Correction [Text Block] Restatement of Previously Issued Unaudited Condensed Financial Statements Basis of Accounting [Text Block] Basis of Presentation of Interim Unaudited Financial Statements Use of Estimates, Policy [Policy Text Block] Use of Estimates Earnings Per Share, Policy [Policy Text Block] Basic and Diluted Net (Loss) per Share Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Disclosure of accounting policy for issuance costs associated with equity issuances. Issuance Costs Associated with Equity Issuances [Policy Text Block] Issuance Costs Associated with Equity Issuances Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Research, Development, and Computer Software, Policy [Policy Text Block] Research and Development Share-based Payment Arrangement [Policy Text Block] Stock-Based Compensation Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of prepaid expenses and other current assets Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of shares excluded from the computation of diluted weighted-average shares outstanding Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Schedule of Restatement of Previously Issued Unaudited Condensed Financial Statements Schedule of Stock by Class [Table] Class of Stock [Line Items] Stockholders' Equity No definition available. Nature of Business and Liquidity [Abstract] Nature of Business and Liquidity Revenue from Contract with Customer, Excluding Assessed Tax Revenue The gross proceeds from the additional capital contribution to the entity through the issuance of common stock. Gross Proceeds from Issuance of Common Stock Gross proceeds from issuance of common shares Fair Value Measurement Inputs and Valuation Techniques [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurements Cash Equivalents, at Carrying Value Cash equivalents, Carrying Value Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents, Fair Value Other Prepaid Expense, Current Prepaid expenses Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Research and Development Expense, Current Prepaid clinical trial expenses Prepaid Insurance Prepaid insurance Security Deposit Security deposits and other Employee-related Liabilities, Current Payroll and related benefits Accrued Professional Fees, Current Accrued professional and clinical fees Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Commitments and Contingencies Lease, Cost [Abstract] Leases Operating Lease, Expense Rental expense Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Title of Individual [Axis] Title of Individual [Domain] Executive Officers Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Commitments and Contingencies Deferred Compensation Arrangements [Abstract] Employment Agreements The maximum aggregate severance payments payable to executive officers under the terms of employment agreements. Maximum Aggregate Severance Payments Maximum aggregate severance payments Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to an "At the Market" Equity Offering. At the Market Equity Offering [Member] At the Market Equity Offering Represents information pertaining to a sales agreement with Bank of America and Think Equity LLC. Bank of America and Think Equity LLC Sales Agreement Private Placement [Member] Private placement Number of classes of stock designated. Number of classes of stock designated Number of classes of stock designated The maximum number of shares permitted to be issued by an entity's charter and bylaws. Common Stock And Preferred Stock, Shares Authorized Number of common and preferred shares authorized The authorized value of common shares which may be sold under the terms of the At the Market (ATM) Equity Offering. At the Market Equity Offering, Common Stock, Authorized Value Aggregate offering price Sale of Stock, Price Per Share Price per share Number of vote for each share of common stock. Number of Votes for Each Share of Common Stock Number of vote for each share of common stock Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to Underwriters warrants. Underwriters warrants EX-101.PRE 10 anvs-20230630_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2023	Aug. 11, 2023
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-39202
Entity Registrant Name	Annovis Bio, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-2540421
Entity Address, Address Line One	1055 Westlakes Drive, Suite 300
Entity Address, City or Town	Berwyn
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19312
City Area Code	610
Local Phone Number	727-3913
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	ANVS
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,012,273
Entity Central Index Key	0001477845
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 15,724,629		$ 28,377,693	$ 35,974,251
Prepaid expenses and other current assets	7,091,855		7,644,376	3,992,967
Total current assets	22,816,484		36,022,069	39,967,218
Total assets	22,816,484		36,022,069	39,967,218
Current liabilities:
Accounts payable	1,172,877		3,961,254	901,841
Accrued expenses	900,972		3,737,285	397,544
Total current liabilities	2,073,849		7,698,539	1,299,385
Total liabilities	2,073,849		7,698,539	1,299,385
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding
Common stock - $0.0001 par value, 70,000,000 and 35,000,000 shares authorized and 9,012,273 and 8,163,923 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	902		816	816
Additional paid-in capital	94,070,810		82,377,488	78,563,673
Accumulated deficit	(73,329,077)		(54,054,774)	(39,896,656)
Total stockholders' equity	20,742,635	$ 20,136,073	28,323,530	38,667,833	$ 42,700,458	$ 44,494,964
Total liabilities and stockholders' equity	$ 22,816,484		$ 36,022,069	$ 39,967,218

XML 13 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Balance Sheets
Preferred stock, par value (dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,000,000	2,000,000	2,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value (dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	70,000,000	35,000,000	35,000,000
Common stock, shares issued	9,012,273	8,163,923	8,163,923	8,100,570
Common stock, shares outstanding	9,012,273	8,163,923	8,163,923	8,100,570

XML 14 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 8,262,167		$ 4,033,963		$ 16,048,223	$ 6,183,604
General and administrative	1,497,533		1,938,447		3,681,193	5,042,518
Total operating expenses	9,759,700		5,972,410		19,729,416	11,226,122
Operating loss	(9,759,700)		(5,972,410)		(19,729,416)	(11,226,122)
Other income:
Interest income, net	222,578		36,024		455,113	55,673
Total other income	222,578		36,024		455,113	55,673
Loss before income taxes	(9,537,122)		(5,936,386)		(19,274,303)	(11,170,449)
Income tax expense (benefit)	0		0		0	0
Net loss	$ (9,537,122)	$ (9,737,181)	$ (5,936,386)	$ (5,234,063)	$ (19,274,303)	$ (11,170,449)
Basic loss per common share	$ (1.07)		$ (0.73)		$ (2.25)	$ (1.37)
Diluted loss per common share	$ (1.07)		$ (0.73)		$ (2.25)	$ (1.37)
Weighted average number of common shares outstanding, basic	8,951,309		8,163,923		8,575,239	8,160,702
Weighted average number of common shares outstanding, diluted	8,951,309		8,163,923		8,575,239	8,160,702

XML 15 R5.htm IDEA: XBRL DOCUMENT

Statements of Changes in Stockholders' Equity - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2021	$ 810	$ 73,220,361	$ (28,726,207)	$ 44,494,964
Balance, shares at Dec. 31, 2021	8,100,570
Changes in Stockholders' Equity
Exercise of stock options	$ 6	4,607		4,613
Exercise of stock options, shares	63,353
Stock-based compensation expense		3,434,944		3,434,944
Net and comprehensive loss			(5,234,063)	(5,234,063)
Balance at Mar. 31, 2022	$ 816	76,659,912	(33,960,270)	42,700,458
Balance, shares at Mar. 31, 2022	8,163,923
Balance at Dec. 31, 2021	$ 810	73,220,361	(28,726,207)	44,494,964
Balance, shares at Dec. 31, 2021	8,100,570
Changes in Stockholders' Equity
Net and comprehensive loss				(11,170,449)
Balance at Jun. 30, 2022	$ 816	78,563,673	(39,896,656)	38,667,833
Balance, shares at Jun. 30, 2022	8,163,923
Balance at Mar. 31, 2022	$ 816	76,659,912	(33,960,270)	42,700,458
Balance, shares at Mar. 31, 2022	8,163,923
Changes in Stockholders' Equity
Stock-based compensation expense		1,903,761		1,903,761
Net and comprehensive loss			(5,936,386)	(5,936,386)
Balance at Jun. 30, 2022	$ 816	78,563,673	(39,896,656)	38,667,833
Balance, shares at Jun. 30, 2022	8,163,923
Balance at Dec. 31, 2022	$ 816	82,377,488	(54,054,774)	28,323,530
Balance, shares at Dec. 31, 2022	8,163,923
Changes in Stockholders' Equity
Exercise of stock options	$ 6	7,380		7,386
Exercise of stock options, shares	52,755
Stock-based compensation expense		1,542,338		1,542,338
Net and comprehensive loss			(9,737,181)	(9,737,181)
Balance at Mar. 31, 2023	$ 822	83,927,206	(63,791,955)	20,136,073
Balance, shares at Mar. 31, 2023	8,216,678
Balance at Dec. 31, 2022	$ 816	82,377,488	(54,054,774)	28,323,530
Balance, shares at Dec. 31, 2022	8,163,923
Changes in Stockholders' Equity
Net and comprehensive loss				(19,274,303)
Balance at Jun. 30, 2023	$ 902	94,070,810	(73,329,077)	20,742,635
Balance, shares at Jun. 30, 2023	9,012,273
Balance at Mar. 31, 2023	$ 822	83,927,206	(63,791,955)	20,136,073
Balance, shares at Mar. 31, 2023	8,216,678
Changes in Stockholders' Equity
Issuance of common stock, net of issuance costs	$ 79	8,571,112		8,571,191
Issuance of common stock, net of issuance costs, shares	788,453
Exercise of stock options	$ 1	999		1,000
Exercise of stock options, shares	7,142
Stock-based compensation expense		1,571,493		1,571,493
Net and comprehensive loss			(9,537,122)	(9,537,122)
Balance at Jun. 30, 2023	$ 902	$ 94,070,810	$ (73,329,077)	$ 20,742,635
Balance, shares at Jun. 30, 2023	9,012,273

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows	6 Months Ended
Statements of Cash Flows	Jun. 30, 2023 USD ($)
Cash flows from operating activities:
Net loss	$ (19,274,303)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	3,113,831
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	552,521
Accounts payable	(2,788,377)
Accrued expenses	(2,836,313)
Net cash used in operating activities	(21,232,641)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	8,571,191
Proceeds from exercise of stock options	8,386
Net cash provided by financing activities	8,579,577
Net (decrease) increase in cash and cash equivalents	(12,653,064)
Cash and cash equivalents, beginning of year	28,377,693
Cash and cash equivalents, end of period	$ 15,724,629

XML 17 R7.htm IDEA: XBRL DOCUMENT

Nature of Business, Going Concern and Management's Plan

6 Months Ended

Jun. 30, 2023

Nature of Business, Going Concern and Management's Plan

Nature of Business, Going Concern and Management's Plans

(1) Nature of Business, Going Concern and Management’s Plan

The Company’s primary source of capital has been the issuance of equity securities. The Company’s common stock trades on the New York Stock Exchange under the ticker symbol “ANVS”

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2023

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

(b) Use of Estimates

(d) Cash and Cash Equivalents

(e) Issuance Costs Associated with Equity Issuances

(f) Fair Value of Financial Instruments

(g) Research and Development

(h) Stock-Based Compensation

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(i) Income Taxes

(j) Recent Accounting Pronouncements

There are no recent accounting pronouncements that would have a significant impact on the Company’s financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2023

Fair Value Measurements

Fair Value Measurements

(3) Fair Value Measurements

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.


			Fair Value Measurement at
			June 30, 2023
	Carrying Value		Level 1		Level 2		Level 3
Cash equivalents	$	15,655,971	$	15,655,971	$	—	$	—


			Fair Value Measurement at
			December 31, 2022
	Carrying Value		Level 1		Level 2		Level 3
Cash equivalents	$	26,001,934	$	26,001,934	$	—	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

6 Months Ended

Jun. 30, 2023

Prepaid Expenses and Other Current Assets

Prepaid Expenses and Other Current Assets

(4) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:


	June 30,		December 31,
	2023		2022
Prepaid expenses	$	65,269	$	67,532
Prepaid clinical trial expenses		6,895,959		7,528,250
Prepaid insurance		104,605		37,356
Security deposits and other		26,022		11,238
	$	7,091,855	$	7,644,376

XML 21 R11.htm IDEA: XBRL DOCUMENT

Accrued Expenses

6 Months Ended

Jun. 30, 2023

Accrued Expenses

Accrued Expenses

(5) Accrued Expenses

Accrued expenses consisted of the following:


	June 30,		December 31,
	2023		2022
Payroll and related benefits	$	260,287	$	556,827
Accrued professional and clinical fees		640,685		3,180,458
	$	900,972	$	3,737,285

XML 22 R12.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies

Commitments and Contingencies

(6) Commitments and Contingencies

(a) Research & Development

(b) Leases

(d) Litigation

At June 30, 2023, the Company did not have any pending legal actions.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2023

Stockholders' Equity

Stockholders' Equity

(7) Stockholders’ Equity

(a) Overview

(b) Common Stock

1. Dividends

2. Liquidation

3. Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of June 30, 2023 or December 31, 2022.

(d) Warrants

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2023

Stock-Based Compensation

Stock-Based Compensation

(8) Stock-Based Compensation

Stock-based compensation expense was as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
General and administrative	$	644,353	$	1,180,639	$	1,413,455	$	3,425,682
Research and development		927,140		723,122		1,700,376		1,913,023
	$	1,571,493	$	1,903,761	$	3,113,831	$	5,338,705

XML 25 R15.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

6 Months Ended

Jun. 30, 2023

Net Loss Per Share

Net Loss Per Share

(9) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Numerator
Net loss	$	(9,537,122)	$	(5,936,386)	$	(19,274,303)	$	(11,170,449)
Denominator
Weighted-average common shares outstanding, basic and diluted		8,951,309		8,163,923		8,575,239		8,160,702
Net loss per share, basic and diluted	$	(1.07)	$	(0.73)	$	(2.25)	$	(1.37)


	June 30,
	2023	2022
Stock options	1,709,150	1,627,941
Warrants	2,400	2,400

XML 26 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2023

Income Taxes

Income Taxes

(10) Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Restatement of Previously Issued Unaudited Condensed Financial Statements

6 Months Ended

Jun. 30, 2023

Restatement of Previously Issued Unaudited Condensed Financial Statements

Restatement of Previously Issued Unaudited Condensed Financial Statements

(11) Restatement of Previously Issued Unaudited Condensed Financial Statements

The Company noted the following items were improperly expensed during the three and six months ended June 30, 2022:


	As of June 30, 2022
	(unaudited)
	As		Restatement		As
	Reported		Impacts		Restated
Assets
Current assets:
Cash and cash equivalents	$	35,974,251	$		$	35,974,251
Prepaid expenses and other current assets		551,072		3,441,895		3,992,967
Deferred clinical materials		—		—		—
Total current assets		36,525,323		3,441,895		39,967,218
Total assets	$	36,525,323	$	3,441,895	$	39,967,218
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	901,841	$		$	901,841
Accrued expenses		397,544				397,544
Total current liabilities		1,299,385		—		1,299,385
Total liabilities	$	1,299,385	$	—	$	1,299,385
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding		—				—
Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively		816				816
Additional paid-in capital		78,563,673				78,563,673
Accumulated deficit		(43,338,551)		3,441,895		(39,896,656)
Total stockholders' equity		35,225,938		3,441,895		38,667,833
Total liabilities and stockholders' equity	$	36,525,323	$	3,441,895	$	39,967,218


	Three Months Ended June 30, 2022
	As		Restatement		As
	Reported		Impacts		Restated
Operating expenses:
Research and development	$	6,815,708	$	(2,781,745)	$	4,033,963
General and administrative		1,938,447		—		1,938,447
Total operating expenses		8,754,155		(2,781,745)		5,972,410

Operating loss		(8,754,155)		2,781,745		(5,972,410)
Other income:
Interest income		36,024		—		36,024
Grant Income
Total other income		36,024		—		36,024

Loss before income taxes		(8,718,131)		2,781,745		(5,936,386)
Income tax expense (benefit)		—		—		—
Net loss	$	(8,718,131)	$	2,781,745	$	(5,936,386)
Basic and diluted loss per common share	$	(1.07)		—	$	(0.73)
Weighted average number of common shares outstanding, basic and diluted		8,163,923		—		8,163,923


	Six Months Ended June 30, 2022
	As		Restatement		As
	Reported		Impacts		Restated
Operating expenses:
Research and development	$	9,625,499	$	(3,441,895)	$	6,183,604
General and administrative		5,042,518		—		5,042,518
Total operating expenses		14,668,017		(3,441,895)		11,226,122

Operating loss		(14,668,017)		3,441,895		(11,226,122)
Other income:
Interest income		55,673		—		55,673
Grant Income
Total other income		55,673		—		55,673

Loss before income taxes		(14,612,344)		3,441,895		(11,170,449)
Income tax expense (benefit)		—		—		—
Net loss	$	(14,612,344)	$	3,441,895	$	(11,170,449)
Basic and diluted loss per common share	$	(1.79)		—	$	(1.37)
Weighted average number of common shares outstanding, basic and diluted		8,160,702		—		8,160,702


	Six Months Ended June 30, 2022
	As		Restatement	As
	Reported		Impacts	Restated
Cash flows from operating activities:
Net loss	$	(14,612,344)	3,441,895	$	(11,170,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		5,338,705	—		5,338,705
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(235,608)	(3,441,895)		(3,677,503)
Accounts payable		213,767	—		213,767
Accrued expenses		(420,896)	—		(420,896)
Net cash used in operating activities		(9,716,376)	—		(9,716,376)
Cash flows from financing activities:
Proceeds from exercise of stock options		4,613	—		4,613
Net cash used in financing activities		4,613	—		4,613
Net (decrease) increase in cash and cash equivalents		(9,711,763)	—		(9,711,763)
Cash and cash equivalents, beginning of period		45,686,014	—		45,686,014
Cash and cash equivalents, end of period	$	35,974,251	—	$	35,974,251

XML 28 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2023
Summary of Significant Accounting Policies
Basis of Presentation of Interim Unaudited Financial Statements	(a) Basis of Presentation of Interim Unaudited Financial Statements The accompanying interim financial statements of Annovis Bio, Inc. should be read in conjunction with the audited financial statements and notes thereto included in the Company’s 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2023. In the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, the Company restated (i) unaudited condensed balance sheets as of March 31, 2022, June 30, 2022 and September 30, 2022, (ii) unaudited condensed statements of operations and comprehensive loss for the three months ended March 31, 2022, three and six months ended June 30, 2022, and three and nine months ended September 30, 2022, and (iii) unaudited condensed statements of cash flows for the three months ended March 31, 2022, six months ended June 30, 2022 and nine months ended September 30, 2022, in each of the Quarterly Reports on Form 10- Q for the quarterly periods ended March 31, 2022, June 30, 2022 and September 30, 2022 The restatement resulted from the Company's prior accounting for payments for research and development expenses and recognition of expenses. Accordingly, certain amounts for the three and six months ended June 30, 2022 presented herein reflect the restated amounts. The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at June 30, 2023, its results of operations for the three and six months ended June 30, 2023 and 2022 and its cash flows for the six month periods ended June 30, 2023 and 2022. The interim results of operations are not necessarily indicative of the results to be expected for a full year or any future period. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the SEC. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.
Use of Estimates	(b) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates. Significant items subject to such estimates and assumptions include stock-based compensation expense, and prepaid expenses and accrued liabilities that are measured based on progress toward completion of research and development projects. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.
Basic and Diluted Net (Loss) per Share	(c) Basic and Diluted Net (Loss) per Share Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect.
Cash and Cash Equivalents	(d) Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $ 250,000. Any loss incurred or a lack of access to such funds, could have a significant adverse effect on the Company’s financial condition, results of operations and cash flows.
Issuance Costs Associated with Equity Issuances	(e) Issuance Costs Associated with Equity Issuances Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.
Fair Value of Financial Instruments	(f) Fair Value of Financial Instruments The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.
Research and Development	(g) Research and Development Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company’s contracts with its vendors, and are realized in the ordinary course of business
Stock-Based Compensation	(h) Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the fair value of the award and is generally recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company also has options outstanding with a performance-based vesting conditions, for which the Company recognizes expense based on the estimated probability of achievement of the performance metrics over the contractual term of the option. Forfeitures are recognized in compensation expense in the period when they occur. The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.
Income Taxes	(i) Income Taxes The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2023 and December 31, 2022, the Company has recorded a full valuation allowance against its deferred tax assets. The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at June 30, 2023 or December 31, 2022.
Recent Accounting Pronouncements	(j) Recent Accounting Pronouncements There are no recent accounting pronouncements that would have a significant impact on the Company’s financial statements.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2023

Fair Value Measurements

Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis


			Fair Value Measurement at
			June 30, 2023
	Carrying Value		Level 1		Level 2		Level 3
Cash equivalents	$	15,655,971	$	15,655,971	$	—	$	—


			Fair Value Measurement at
			December 31, 2022
	Carrying Value		Level 1		Level 2		Level 3
Cash equivalents	$	26,001,934	$	26,001,934	$	—	$	—

XML 30 R20.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2023

Prepaid Expenses and Other Current Assets

Schedule of prepaid expenses and other current assets

Prepaid expenses and other current assets consisted of the following:


	June 30,		December 31,
	2023		2022
Prepaid expenses	$	65,269	$	67,532
Prepaid clinical trial expenses		6,895,959		7,528,250
Prepaid insurance		104,605		37,356
Security deposits and other		26,022		11,238
	$	7,091,855	$	7,644,376

XML 31 R21.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2023

Accrued Expenses

Schedule of accrued expenses

Accrued expenses consisted of the following:


	June 30,		December 31,
	2023		2022
Payroll and related benefits	$	260,287	$	556,827
Accrued professional and clinical fees		640,685		3,180,458
	$	900,972	$	3,737,285

XML 32 R22.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2023

Stock-Based Compensation

Schedule of stock-based compensation expense

Stock-based compensation expense was as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
General and administrative	$	644,353	$	1,180,639	$	1,413,455	$	3,425,682
Research and development		927,140		723,122		1,700,376		1,913,023
	$	1,571,493	$	1,903,761	$	3,113,831	$	5,338,705

XML 33 R23.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2023

Net Loss Per Share

Schedule of basic and diluted net loss per share

The following table sets forth the computation of basic and diluted net loss per share:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Numerator
Net loss	$	(9,537,122)	$	(5,936,386)	$	(19,274,303)	$	(11,170,449)
Denominator
Weighted-average common shares outstanding, basic and diluted		8,951,309		8,163,923		8,575,239		8,160,702
Net loss per share, basic and diluted	$	(1.07)	$	(0.73)	$	(2.25)	$	(1.37)

Schedule of shares excluded from the computation of diluted weighted-average shares outstanding


	June 30,
	2023	2022
Stock options	1,709,150	1,627,941
Warrants	2,400	2,400

XML 34 R24.htm IDEA: XBRL DOCUMENT

Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)

6 Months Ended

Jun. 30, 2023

Restatement of Previously Issued Unaudited Condensed Financial Statements

Schedule of Restatement of Previously Issued Unaudited Condensed Financial Statements


	As of June 30, 2022
	(unaudited)
	As		Restatement		As
	Reported		Impacts		Restated
Assets
Current assets:
Cash and cash equivalents	$	35,974,251	$		$	35,974,251
Prepaid expenses and other current assets		551,072		3,441,895		3,992,967
Deferred clinical materials		—		—		—
Total current assets		36,525,323		3,441,895		39,967,218
Total assets	$	36,525,323	$	3,441,895	$	39,967,218
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	901,841	$		$	901,841
Accrued expenses		397,544				397,544
Total current liabilities		1,299,385		—		1,299,385
Total liabilities	$	1,299,385	$	—	$	1,299,385
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding		—				—
Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively		816				816
Additional paid-in capital		78,563,673				78,563,673
Accumulated deficit		(43,338,551)		3,441,895		(39,896,656)
Total stockholders' equity		35,225,938		3,441,895		38,667,833
Total liabilities and stockholders' equity	$	36,525,323	$	3,441,895	$	39,967,218


	Three Months Ended June 30, 2022
	As		Restatement		As
	Reported		Impacts		Restated
Operating expenses:
Research and development	$	6,815,708	$	(2,781,745)	$	4,033,963
General and administrative		1,938,447		—		1,938,447
Total operating expenses		8,754,155		(2,781,745)		5,972,410

Operating loss		(8,754,155)		2,781,745		(5,972,410)
Other income:
Interest income		36,024		—		36,024
Grant Income
Total other income		36,024		—		36,024

Loss before income taxes		(8,718,131)		2,781,745		(5,936,386)
Income tax expense (benefit)		—		—		—
Net loss	$	(8,718,131)	$	2,781,745	$	(5,936,386)
Basic and diluted loss per common share	$	(1.07)		—	$	(0.73)
Weighted average number of common shares outstanding, basic and diluted		8,163,923		—		8,163,923


	Six Months Ended June 30, 2022
	As		Restatement		As
	Reported		Impacts		Restated
Operating expenses:
Research and development	$	9,625,499	$	(3,441,895)	$	6,183,604
General and administrative		5,042,518		—		5,042,518
Total operating expenses		14,668,017		(3,441,895)		11,226,122

Operating loss		(14,668,017)		3,441,895		(11,226,122)
Other income:
Interest income		55,673		—		55,673
Grant Income
Total other income		55,673		—		55,673

Loss before income taxes		(14,612,344)		3,441,895		(11,170,449)
Income tax expense (benefit)		—		—		—
Net loss	$	(14,612,344)	$	3,441,895	$	(11,170,449)
Basic and diluted loss per common share	$	(1.79)		—	$	(1.37)
Weighted average number of common shares outstanding, basic and diluted		8,160,702		—		8,160,702


	Six Months Ended June 30, 2022
	As		Restatement	As
	Reported		Impacts	Restated
Cash flows from operating activities:
Net loss	$	(14,612,344)	3,441,895	$	(11,170,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		5,338,705	—		5,338,705
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(235,608)	(3,441,895)		(3,677,503)
Accounts payable		213,767	—		213,767
Accrued expenses		(420,896)	—		(420,896)
Net cash used in operating activities		(9,716,376)	—		(9,716,376)
Cash flows from financing activities:
Proceeds from exercise of stock options		4,613	—		4,613
Net cash used in financing activities		4,613	—		4,613
Net (decrease) increase in cash and cash equivalents		(9,711,763)	—		(9,711,763)
Cash and cash equivalents, beginning of period		45,686,014	—		45,686,014
Cash and cash equivalents, end of period	$	35,974,251	—	$	35,974,251

XML 35 R25.htm IDEA: XBRL DOCUMENT

Nature of Business, Going Concern and Management's Plan (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Nature of Business and Liquidity
Revenue		$ 0
Common Stock
Nature of Business and Liquidity
Issuance of common stock	788,453

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 36 R26.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Fair Value Measurements
Cash equivalents, Carrying Value	$ 15,655,971	$ 26,001,934
Recurring \| Level 1
Fair Value Measurements
Cash equivalents, Fair Value	$ 15,655,971	$ 26,001,934

XML 37 R27.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Prepaid Expenses and Other Current Assets
Prepaid expenses	$ 65,269	$ 67,532
Prepaid clinical trial expenses	6,895,959	7,528,250
Prepaid insurance	104,605	37,356
Security deposits and other	26,022	11,238
Total prepaid expenses and other current assets	$ 7,091,855	$ 7,644,376	$ 3,992,967

XML 38 R28.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Accrued Expenses
Payroll and related benefits	$ 260,287	$ 556,827
Accrued professional and clinical fees	640,685	3,180,458
Total accrued expenses	$ 900,972	$ 3,737,285	$ 397,544

XML 39 R29.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Leases (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Leases
Rental expense	$ 17,712	$ 16,081	$ 35,273	$ 33,358

XML 40 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Employment Agreements (Details)	Jun. 30, 2023 USD ($)
Executive Officers
Employment Agreements
Maximum aggregate severance payments	$ 1,274,500

XML 41 R31.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Overview (Details)	Apr. 07, 2023 USD ($) $ / shares shares	Apr. 04, 2023 USD ($) $ / shares shares	Jun. 30, 2023 item Vote $ / shares shares	Mar. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 $ / shares shares	Jun. 30, 2022 $ / shares shares
Stockholders' Equity
Number of classes of stock designated \| item			2
Number of common and preferred shares authorized			72,000,000
Number of common shares authorized			70,000,000		35,000,000	35,000,000
Common stock, par value (dollars per share) \| $ / shares			$ 0.0001		$ 0.0001	$ 0.0001
Number of preferred shares authorized			2,000,000		2,000,000	2,000,000
Preferred stock, par value (dollars per share) \| $ / shares			$ 0.0001		$ 0.0001	$ 0.0001
Number of vote for each share of common stock \| Vote			1
Preferred stock, shares issued			0		0	0
Preferred stock, shares outstanding			0		0	0
At the Market Equity Offering
Stockholders' Equity
Common stock, par value (dollars per share) \| $ / shares				$ 0.0001
Aggregate offering price \| $				$ 50,000,000.0
Bank of America and Think Equity LLC Sales Agreement
Stockholders' Equity
Issuance of common stock		704,000
Price per share \| $ / shares		$ 10.88
Gross proceeds from issuance of common shares \| $		$ 7,659,520
Private placement
Stockholders' Equity
Issuance of common stock	84,453
Price per share \| $ / shares	$ 12.61
Gross proceeds from issuance of common shares \| $	$ 1,060,000.00

XML 42 R32.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Warrants (Details) - $ / shares	3 Months Ended		6 Months Ended
Stockholders' Equity - Warrants (Details) - $ / shares	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Jan. 31, 2020
Warrants
Warrants outstanding	2,400		2,400		2,400
Number of warrants exercised	0	0	0	0
Underwriters warrants
Warrants
Number of warrants issued						100,000
Exercise price						$ 7.50
Percentage of exercise price to the share offering price						125.00%
Warrant term						5 years

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
Stock-Based Compensation (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Jun. 01, 2021	May 31, 2021
Stock-Based Compensation
Stock-based compensation expense	$ 1,571,493	$ 1,903,761	$ 3,113,831	$ 5,338,705
General and administrative
Stock-Based Compensation
Stock-based compensation expense	644,353	1,180,639	1,413,455	3,425,682
Research and development
Stock-Based Compensation
Stock-based compensation expense	$ 927,140	$ 723,122	$ 1,700,376	$ 1,913,023
Stock Options
Stock-Based Compensation
Options granted			111,705
Weighted average exercise price			$ 13.29
Weighted average grant date fair value			$ 11.72
Exercise of stock options, shares	7,142	0	59,897	70,101
Options outstanding	1,709,150		1,709,150		1,657,342
Options, vested and exercisable	1,426,229		1,426,229		1,310,667
Stock Options \| Weighted average
Stock-Based Compensation
Expected term (in years)			5 years 7 months 6 days
Risk-free interest rate			3.55%
Expected volatility			128.60%
Dividend yield (as a percent)			0.00%
Stock Options \| Immediate Vesting
Stock-Based Compensation
Options granted			30,000
Term of award (in years)			10 years
Stock Options \| Service-based vesting, quarterly installments
Stock-Based Compensation
Vesting period			2 years
Term of award (in years)			10 years
Previous Plans
Stock-Based Compensation
Shares available for future grants	0		0
2019 Plan
Stock-Based Compensation
Shares authorized						2,000,000	1,000,000
Shares available for future grants	281,169		281,169

XML 44 R34.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Basic and diluted net loss per share (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator
Net loss	$ (9,537,122)	$ (9,737,181)	$ (5,936,386)	$ (5,234,063)	$ (19,274,303)	$ (11,170,449)
Denominator
Weighted-average common shares outstanding, basic	8,951,309		8,163,923		8,575,239	8,160,702
Weighted-average common shares outstanding, diluted	8,951,309		8,163,923		8,575,239	8,160,702
Net loss per share, basic	$ (1.07)		$ (0.73)		$ (2.25)	$ (1.37)
Net loss per share, diluted	$ (1.07)		$ (0.73)		$ (2.25)	$ (1.37)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 45 R35.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Potential shares excluded from calculation (Details) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Stock Options
Net Loss Per Share
Antidilutive securities excluded from computation of earnings per share	1,709,150	1,627,941
Warrants
Net Loss Per Share
Antidilutive securities excluded from computation of earnings per share	2,400	2,400

XML 46 R36.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Income Taxes
Income tax expense (benefit)	$ 0	$ 0	$ 0	$ 0
Liability for uncertain tax positions			0		$ 0
Accrued interest or penalties	$ 0		$ 0		$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 47 R37.htm IDEA: XBRL DOCUMENT

Restatement of Previously Issued Unaudited Condensed Financial Statements (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Restatement of Previously Issued Unaudited Condensed Financial Statements
Prepaid expenses and other current assets	$ 7,091,855		$ 3,992,967		$ 7,091,855	$ 3,992,967	$ 7,644,376
Accrued expenses and other current liabilities	900,972		397,544		900,972	397,544	$ 3,737,285
Total operating expenses	9,759,700		5,972,410		19,729,416	11,226,122
Net loss	$ (9,537,122)	$ (9,737,181)	(5,936,386)	$ (5,234,063)	$ (19,274,303)	(11,170,449)
Restatement Impacts
Restatement of Previously Issued Unaudited Condensed Financial Statements
Aggregate amount reclassified from research and development expense to prepaid expenses and other current assets			2,883,977
Prepaid expenses and other current assets			3,441,895			3,441,895
Additional expense for research and development recognized in prepaid expenses and other current assets			102,232
Total operating expenses			(2,781,745)			(3,441,895)
Net loss			$ 2,781,745			$ 3,441,895

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 48 R38.htm IDEA: XBRL DOCUMENT

Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details) - USD ($)	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 15,724,629		$ 28,377,693	$ 35,974,251
Prepaid expenses and other current assets	7,091,855		7,644,376	3,992,967
Total current assets	22,816,484		36,022,069	39,967,218
Total assets	22,816,484		36,022,069	39,967,218
Current liabilities:
Accounts payable	1,172,877		3,961,254	901,841
Accrued expenses	900,972		3,737,285	397,544
Total current liabilities	2,073,849		7,698,539	1,299,385
Total liabilities	2,073,849		7,698,539	1,299,385
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding
Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	902		816	816
Additional paid-in capital	94,070,810		82,377,488	78,563,673
Accumulated deficit	(73,329,077)		(54,054,774)	(39,896,656)
Total stockholders' equity	20,742,635	$ 20,136,073	28,323,530	38,667,833	$ 42,700,458	$ 44,494,964
Total liabilities and stockholders' equity	$ 22,816,484		$ 36,022,069	39,967,218
As Reported
Current assets:
Cash and cash equivalents				35,974,251
Prepaid expenses and other current assets				551,072
Total current assets				36,525,323
Total assets				36,525,323
Current liabilities:
Accounts payable				901,841
Accrued expenses				397,544
Total current liabilities				1,299,385
Total liabilities				1,299,385
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding
Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively				816
Additional paid-in capital				78,563,673
Accumulated deficit				(43,338,551)
Total stockholders' equity				35,225,938
Total liabilities and stockholders' equity				36,525,323
Restatement Impacts
Current assets:
Prepaid expenses and other current assets				3,441,895
Total current assets				3,441,895
Total assets				3,441,895
Current liabilities:
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding
Accumulated deficit				3,441,895
Total stockholders' equity				3,441,895
Total liabilities and stockholders' equity				$ 3,441,895

XML 49 R39.htm IDEA: XBRL DOCUMENT

Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details) - $ / shares	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Restatement of Previously Issued Unaudited Condensed Financial Statements
Preferred stock, par value (dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,000,000	2,000,000	2,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value (dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	70,000,000	35,000,000	35,000,000
Common stock, shares issued	9,012,273	8,163,923	8,163,923	8,100,570
Common stock, shares outstanding	9,012,273	8,163,923	8,163,923	8,100,570

XML 50 R40.htm IDEA: XBRL DOCUMENT

Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 8,262,167		$ 4,033,963		$ 16,048,223	$ 6,183,604
General and administrative	1,497,533		1,938,447		3,681,193	5,042,518
Total operating expenses	9,759,700		5,972,410		19,729,416	11,226,122
Operating loss	(9,759,700)		(5,972,410)		(19,729,416)	(11,226,122)
Other income:
Interest income	222,578		36,024		455,113	55,673
Total other income	222,578		36,024		455,113	55,673
Loss before income taxes	(9,537,122)		(5,936,386)		(19,274,303)	(11,170,449)
Income tax expense (benefit)	0		0		0	0
Net loss	$ (9,537,122)	$ (9,737,181)	$ (5,936,386)	$ (5,234,063)	$ (19,274,303)	$ (11,170,449)
Basic loss per common share	$ (1.07)		$ (0.73)		$ (2.25)	$ (1.37)
Diluted loss per common share	$ (1.07)		$ (0.73)		$ (2.25)	$ (1.37)
Weighted average number of common shares outstanding, basic	8,951,309		8,163,923		8,575,239	8,160,702
Weighted average number of common shares outstanding, diluted	8,951,309		8,163,923		8,575,239	8,160,702
As Reported
Operating expenses:
Research and development			$ 6,815,708			$ 9,625,499
General and administrative			1,938,447			5,042,518
Total operating expenses			8,754,155			14,668,017
Operating loss			(8,754,155)			(14,668,017)
Other income:
Interest income			36,024			55,673
Total other income			36,024			55,673
Loss before income taxes			(8,718,131)			(14,612,344)
Net loss			$ (8,718,131)			$ (14,612,344)
Basic loss per common share			$ (1.07)			$ (1.79)
Diluted loss per common share			$ (1.07)			$ (1.79)
Weighted average number of common shares outstanding, basic			8,163,923			8,160,702
Weighted average number of common shares outstanding, diluted			8,163,923			8,160,702
Restatement Impacts
Operating expenses:
Research and development			$ (2,781,745)			$ (3,441,895)
Total operating expenses			(2,781,745)			(3,441,895)
Operating loss			2,781,745			3,441,895
Other income:
Loss before income taxes			2,781,745			3,441,895
Net loss			$ 2,781,745			$ 3,441,895

XML 51 R41.htm IDEA: XBRL DOCUMENT

Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (19,274,303)	$ (11,170,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	3,113,831	5,338,705
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	552,521	(3,677,503)
Accounts payable	(2,788,377)	213,767
Accrued expenses	(2,836,313)	(420,896)
Net cash used in operating activities	(21,232,641)	(9,716,376)
Cash flows from financing activities:
Proceeds from exercise of stock options	8,386	4,613
Net cash provided by financing activities	8,579,577	4,613
Net (decrease) increase in cash and cash equivalents	(12,653,064)	(9,711,763)
Cash and cash equivalents, beginning of year	28,377,693	45,686,014
Cash and cash equivalents, end of period	$ 15,724,629	35,974,251
As Reported
Cash flows from operating activities:
Net loss		(14,612,344)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		5,338,705
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(235,608)
Accounts payable		213,767
Accrued expenses		(420,896)
Net cash used in operating activities		(9,716,376)
Cash flows from financing activities:
Proceeds from exercise of stock options		4,613
Net cash provided by financing activities		4,613
Net (decrease) increase in cash and cash equivalents		(9,711,763)
Cash and cash equivalents, beginning of year		45,686,014
Cash and cash equivalents, end of period		35,974,251
Restatement Impacts
Cash flows from operating activities:
Net loss		3,441,895
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		$ (3,441,895)

XML 52 anvs-20230630x10q_htm.xml IDEA: XBRL DOCUMENT 0001477845 2022-01-01 2022-12-31 0001477845 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001477845 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001477845 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001477845 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001477845 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001477845 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001477845 us-gaap:RetainedEarningsMember 2023-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001477845 us-gaap:RetainedEarningsMember 2023-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001477845 2023-03-31 0001477845 us-gaap:RetainedEarningsMember 2022-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001477845 us-gaap:RetainedEarningsMember 2022-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001477845 us-gaap:RetainedEarningsMember 2022-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001477845 2022-03-31 0001477845 us-gaap:RetainedEarningsMember 2021-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001477845 us-gaap:CommonStockMember 2023-06-30 0001477845 us-gaap:CommonStockMember 2023-03-31 0001477845 us-gaap:CommonStockMember 2022-12-31 0001477845 us-gaap:CommonStockMember 2022-06-30 0001477845 us-gaap:CommonStockMember 2022-03-31 0001477845 us-gaap:CommonStockMember 2021-12-31 0001477845 us-gaap:EmployeeStockOptionMember 2023-06-30 0001477845 us-gaap:EmployeeStockOptionMember 2022-12-31 0001477845 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001477845 anvs:PreviousPlansMember 2023-06-30 0001477845 anvs:EquityIncentivePlan2019Member 2023-06-30 0001477845 anvs:EquityIncentivePlan2019Member 2021-06-01 0001477845 anvs:EquityIncentivePlan2019Member 2021-05-31 0001477845 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001477845 us-gaap:EmployeeStockOptionMember anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember 2023-01-01 2023-06-30 0001477845 us-gaap:EmployeeStockOptionMember anvs:QuarterlyInstallmentVestingMember 2023-01-01 2023-06-30 0001477845 us-gaap:PrivatePlacementMember 2023-04-07 0001477845 anvs:BankOfAmericaAndThinkEquityLlcSalesAgreementMember 2023-04-04 0001477845 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001477845 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001477845 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001477845 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001477845 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-01-01 2022-06-30 0001477845 srt:ScenarioPreviouslyReportedMember 2022-04-01 2022-06-30 0001477845 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-06-30 0001477845 srt:ScenarioPreviouslyReportedMember 2021-12-31 0001477845 2021-12-31 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001477845 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001477845 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001477845 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001477845 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001477845 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001477845 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001477845 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001477845 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001477845 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001477845 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001477845 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001477845 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001477845 2023-01-01 2023-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001477845 2022-01-01 2022-03-31 0001477845 2023-08-11 0001477845 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-06-30 0001477845 anvs:UnderwritersWarrantsMember 2020-01-31 0001477845 srt:ExecutiveOfficerMember 2023-06-30 0001477845 us-gaap:PrivatePlacementMember 2023-04-07 2023-04-07 0001477845 anvs:BankOfAmericaAndThinkEquityLlcSalesAgreementMember 2023-04-04 2023-04-04 0001477845 2023-04-01 2023-06-30 0001477845 2023-01-01 2023-06-30 0001477845 2022-04-01 2022-06-30 0001477845 2022-01-01 2022-06-30 0001477845 anvs:AtMarketEquityOfferingMember 2023-03-31 0001477845 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-04-01 2022-06-30 0001477845 2023-06-30 0001477845 2022-12-31 0001477845 srt:ScenarioPreviouslyReportedMember 2022-06-30 0001477845 2022-06-30 iso4217:USD shares anvs:item anvs:Vote pure iso4217:USD shares

8951309

8163923

8575239

8160702

8951309

8163923

8575239

8160702

0001477845 --12-31 2023 Q2 false

8163923

NYSE Non-accelerated Filer

8163923

9012273

-1.07

-0.73

-2.25

-1.37

0.0001

P10Y

-1.07

-0.73

-2.25

-1.37

8100570

8163923

-1.07

-0.73

-1.79

-1.37

10-Q true 2023-06-30 false 001-39202 Annovis Bio, Inc. DE 26-2540421 1055 Westlakes Drive, Suite 300 Berwyn PA 19312 610 727-3913 Common Stock, par value $0.0001 per share ANVS Yes Yes true true true false 9012273

15724629

28377693

7091855 7644376

22816484

36022069

22816484

36022069

1172877

3961254

900972 3737285

2073849

7698539

2073849

7698539

0.0001

2000000

0.0001

70000000

35000000

9012273

902

816

94070810

82377488

-73329077

-54054774

20742635

28323530

22816484

36022069

8262167

4033963

16048223

6183604

1497533

1938447

3681193

5042518

9759700

5972410

19729416

11226122

-9759700

-5972410

-19729416

-11226122

222578

36024

455113

55673

222578

36024

455113

55673

-9537122

-5936386

-19274303

-11170449

-9537122

-5936386

-19274303

-11170449

-1.07

-0.73

-2.25

-1.37

8951309

8163923

8575239

8160702

8163923

816

82377488

-54054774

28323530

52755

7380

7386

1542338

-9737181

8216678

822

83927206

-63791955

20136073

788453

8571112

8571191

7142

999

1000

1571493

-9537122

9012273

902

94070810

-73329077

20742635

8100570

810

73220361

-28726207

44494964

63353

4607

4613

3434944

-5234063

8163923

816

76659912

-33960270

42700458

1903761

-5936386

8163923

816

78563673

-39896656

38667833

-19274303

-11170449

3113831

5338705

-552521

3677503

-2788377

213767

-2836313

-420896

-21232641

-9716376

8571191

8386

4613

8579577

4613

-12653064

-9711763

28377693

45686014

15724629

35974251

(1) Nature of Business, Going Concern and Management’s PlanAnnovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company’s lead product candidate, buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. The Company has shown in its clinical and pre-clinical studies that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.The Company’s primary source of capital has been the issuance of equity securities. The Company’s common stock trades on the New York Stock Exchange under the ticker symbol “ANVS”At present, the Company lacks sufficient capital on hand to fund its operations for the next 12 months and will need to raise additional capital to ensure its continuity of operations. The Company believes that its current cash and cash equivalents will be sufficient to fund its operations into the first quarter of 2024, including its ongoing Phase 2/3 AD Trial and its ongoing Phase 3 PD Trial. The Company plans to raise additional capital to complete the development and commercialization of its product candidates through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives; however, there can be no assurance that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. The failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on the Company’s business, results of operations, and financial condition. Accordingly, management has concluded that substantial doubt exists with respect to the Company's ability to continue as a going concern for one year after the date that these financial statements are issued.The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

(2) Summary of Significant Accounting Policies(a) Basis of Presentation of Interim Unaudited Financial StatementsThe accompanying interim financial statements of Annovis Bio, Inc. should be read in conjunction with the audited financial statements and notes thereto included in the Company’s 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2023. In the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, the Company restated (i) unaudited condensed balance sheets as of March 31, 2022, June 30, 2022 and September 30, 2022, (ii) unaudited condensed statements of operations and comprehensive loss for the three months ended March 31, 2022, three and six months ended June 30, 2022, and three and nine months ended September 30, 2022, and (iii) unaudited condensed statements of cash flows for the three months ended March 31, 2022, six months ended June 30, 2022 and nine months ended September 30, 2022, in each of the Quarterly Reports on Form 10- Q for the quarterly periods ended March 31, 2022, June 30, 2022 and September 30, 2022 The restatement resulted from the Company's prior accounting for payments for research and development expenses and recognition of expenses. Accordingly, certain amounts for the three and six months ended June 30, 2022 presented herein reflect the restated amounts. The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at June 30, 2023, its results of operations for the three and six months ended June 30, 2023 and 2022 and its cash flows for the six month periods ended June 30, 2023 and 2022. The interim results of operations are not necessarily indicative of the results to be expected for a full year or any future period. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the SEC. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.(b) Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.Significant items subject to such estimates and assumptions include stock-based compensation expense, and prepaid expenses and accrued liabilities that are measured based on progress toward completion of research and development projects. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.(c) Basic and Diluted Net (Loss) per ShareBasic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect.(d) Cash and Cash EquivalentsThe Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $ 250,000. Any loss incurred or a lack of access to such funds, could have a significant adverse effect on the Company’s financial condition, results of operations and cash flows. (e) Issuance Costs Associated with Equity IssuancesIssuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. (f) Fair Value of Financial InstrumentsThe Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature. (g) Research and DevelopmentResearch and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company’s contracts with its vendors, and are realized in the ordinary course of business(h) Stock-Based CompensationStock-based compensation cost is measured at the grant date based on the fair value of the award and is generally recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company also has options outstanding with a performance-based vesting conditions, for which the Company recognizes expense based on the estimated probability of achievement of the performance metrics over the contractual term of the option. Forfeitures are recognized in compensation expense in the period when they occur.The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.(i) Income TaxesThe Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2023 and December 31, 2022, the Company has recorded a full valuation allowance against its deferred tax assets.The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at June 30, 2023 or December 31, 2022.(j) Recent Accounting PronouncementsThere are no recent accounting pronouncements that would have a significant impact on the Company’s financial statements.

(a) Basis of Presentation of Interim Unaudited Financial StatementsThe accompanying interim financial statements of Annovis Bio, Inc. should be read in conjunction with the audited financial statements and notes thereto included in the Company’s 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2023. In the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, the Company restated (i) unaudited condensed balance sheets as of March 31, 2022, June 30, 2022 and September 30, 2022, (ii) unaudited condensed statements of operations and comprehensive loss for the three months ended March 31, 2022, three and six months ended June 30, 2022, and three and nine months ended September 30, 2022, and (iii) unaudited condensed statements of cash flows for the three months ended March 31, 2022, six months ended June 30, 2022 and nine months ended September 30, 2022, in each of the Quarterly Reports on Form 10- Q for the quarterly periods ended March 31, 2022, June 30, 2022 and September 30, 2022 The restatement resulted from the Company's prior accounting for payments for research and development expenses and recognition of expenses. Accordingly, certain amounts for the three and six months ended June 30, 2022 presented herein reflect the restated amounts. The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at June 30, 2023, its results of operations for the three and six months ended June 30, 2023 and 2022 and its cash flows for the six month periods ended June 30, 2023 and 2022. The interim results of operations are not necessarily indicative of the results to be expected for a full year or any future period. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and the rules and regulations of the SEC. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.Significant items subject to such estimates and assumptions include stock-based compensation expense, and prepaid expenses and accrued liabilities that are measured based on progress toward completion of research and development projects. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

(c) Basic and Diluted Net (Loss) per ShareBasic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion of securities that would have an anti-dilutive effect.

(d) Cash and Cash EquivalentsThe Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $ 250,000. Any loss incurred or a lack of access to such funds, could have a significant adverse effect on the Company’s financial condition, results of operations and cash flows.

(e) Issuance Costs Associated with Equity IssuancesIssuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed.

(f) Fair Value of Financial InstrumentsThe Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses. Cash and cash equivalents are reported at fair value. The recorded carrying amounts of accounts payable and accrued expenses reflect their fair value due to their short-term nature.

(g) Research and DevelopmentResearch and development costs are either expensed as incurred or recorded separately as a prepaid asset, and the expense recognized when the service is performed and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company’s contracts with its vendors, and are realized in the ordinary course of business

(h) Stock-Based CompensationStock-based compensation cost is measured at the grant date based on the fair value of the award and is generally recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company also has options outstanding with a performance-based vesting conditions, for which the Company recognizes expense based on the estimated probability of achievement of the performance metrics over the contractual term of the option. Forfeitures are recognized in compensation expense in the period when they occur.The Company uses the Black-Scholes option pricing model to value its option awards which requires the use of assumptions, including the expected life of the option and expected share price volatility. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(i) Income TaxesThe Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of June 30, 2023 and December 31, 2022, the Company has recorded a full valuation allowance against its deferred tax assets.The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions at June 30, 2023 or December 31, 2022.

(j) Recent Accounting PronouncementsThere are no recent accounting pronouncements that would have a significant impact on the Company’s financial statements.

(3) Fair Value MeasurementsThe Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;margin:0pt;padding:0pt;">Fair Value Measurement at </td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, 2023</td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Carrying Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="vertical-align:bottom;width:45.87%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 15,655,971</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 15,655,971</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;margin:0pt;padding:0pt;">Fair Value Measurement at </td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Carrying Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="vertical-align:bottom;width:45.87%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 26,001,934</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 26,001,934</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr></table>

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;margin:0pt;padding:0pt;">Fair Value Measurement at </td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, 2023</td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Carrying Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="vertical-align:bottom;width:45.87%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 15,655,971</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 15,655,971</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;margin:0pt;padding:0pt;">Fair Value Measurement at </td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2022</td></tr><tr><td style="vertical-align:bottom;width:45.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Carrying Value</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 1</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 2</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Level 3</td></tr><tr><td style="vertical-align:bottom;width:45.87%;background:#cceeff;margin:0pt;padding:0pt;">Cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 26,001,934</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 26,001,934</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr></table>

15655971

26001934

(4) Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;">Prepaid expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 65,269</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 67,532</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;">Prepaid clinical trial expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 6,895,959</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 7,528,250</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;">Prepaid insurance</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 104,605</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 37,356</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;">Security deposits and other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 26,022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,238</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,091,855</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,644,376</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>

Prepaid expenses and other current assets consisted of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;">Prepaid expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 65,269</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 67,532</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;">Prepaid clinical trial expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 6,895,959</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 7,528,250</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;">Prepaid insurance</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 104,605</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 37,356</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;">Security deposits and other</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 26,022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,238</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,091,855</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,644,376</td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>

65269

67532

6895959 7528250

104605

37356

26022

11238

7091855 7644376

(5) Accrued ExpensesAccrued expenses consisted of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;">Payroll and related benefits</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"> 260,287</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 556,827</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;">Accrued professional and clinical fees</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 640,685</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,180,458</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 900,972</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,737,285</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>

Accrued expenses consisted of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;">Payroll and related benefits</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"> 260,287</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 556,827</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;margin:0pt;padding:0pt;">Accrued professional and clinical fees</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 640,685</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,180,458</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 900,972</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,737,285</td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>

260287

556827

640685

3180458

900972 3737285

(6) Commitments and Contingencies(a) Research & DevelopmentThe Company has entered into contracts with contract research organizations (CROs) and contract manufacturers (CMOs) related the Company's clinical trials. The contracts require upfront payments, milestone payments, and pass through cost reimbursement, to be made. While the contracts are cancellable with (written) notice, the Company is obligated for payments for services rendered through the termination date of the project with the CRO/CMO.(b) LeasesThe Company leases its office facilities under a month-to-month operating lease. Total rental expense was $17,712 and $16,081 for the three months ended June 30, 2023 and 2022, respectively, and $35,273 and $33,358 for the six months ended June 30, 2023 and 2022, respectively(c) Employment AgreementsThe Company has agreements with its executive officers that provide for severance payments to the employee upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreements were approximately $1,274,500 at June 30, 2023. (d) LitigationThe Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. At June 30, 2023, the Company did not have any pending legal actions.

17712

16081

35273

33358

1274500

(7) Stockholders’ Equity(a) OverviewThe Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company’s initial public offering (the “IPO”) and amended on June 15, 2023 to increase the authorized number of shares. Currently, there are authorized of two classes of stock designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 72,000,000, each with a par value of $0.0001 per share. Of these shares, 70,000,000 shall be common stock and 2,000,000 shall be preferred stock.On March 31, 2023, the “Company, entered into an ATM Equity Offering Sales Agreement SM (the “Sales Agreement”) with BofA Securities, Inc. (“BofA”) and ThinkEquity LLC (“ThinkEquity” and, together with BofA, the “Sales Agents”), as sales agents, pursuant to which the Company may offer and sell, from time to time through the Sales Agents, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50.0 million.On April 4, 2023, the Company delivered written notice to BofA and ThinkEquity to terminate the Sales Agreement, effective April 9, 2023, pursuant to Section 9(a) of the Sales Agreement. The Company is not subject to any termination penalties related to the termination of the Sales Agreement.Prior to termination of the Sales Agreement, the Company sold 704,000 shares of Common Stock pursuant to the Sales Agreement at a price of $10.88 per share, for gross proceeds of $7,659,520 before commissions. As a result of the termination of the Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the Sales Agreement.In addition, on April 7, 2023, the Company sold 84,453 shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $12.61 per share, for aggregate proceeds of $ 1.06 million.(b) Common Stock1. DividendsSubject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.2. LiquidationSubject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.3. VotingThe holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.(c) Preferred StockPreferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of June 30, 2023 or December 31, 2022.(d) WarrantsIn conjunction with the closing of the Company’s IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which was 125% of the initial public offering price. The warrants have a five-year term and were exercisable as of January 29, 2021 and have been classified by the Company as a component of stockholders’ equity. As of June 30, 2023 and December 31, 2022, 2,400 of the warrants were outstanding. No warrants were exercised during the three or six months ended June 30, 2023 or 2022.

2 72000000

0.0001

70000000

2000000

0.0001

50000000.0

704000

10.88

7659520

84453

12.61

1060000.00 1

100000

7.50

1.25

P5Y

2400

0 0 0 0

(8) Stock-Based CompensationThe Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective on January 31, 2020, succeeding the Company’s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 1, 2021, the 2019 Plan was amended to increase the number of shares authorized to be issued from 1,000,000 to 2,000,000. As of June 30, 2023, 281,169 shares were available for future grants.Stock-based compensation expense was as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.87%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.87%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:52.13%;background:#cceeff;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 644,353</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 1,180,639</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 1,413,455</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 3,425,682</td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 927,140</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 723,122</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,700,376</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,913,023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,571,493</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,903,761</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,113,831</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,338,705</td></tr></table>During the six months ended June 30, 2023, the Company granted options to purchase 111,705 shares of common stock at a weighted-average exercise price of $13.29 per share to employees. Under the grant agreements, 30,000 of the options vested immediately and have a 10-year term. The rest of the options have service based vesting conditions and generally vest in substantially equal quarterly installments over two years and have a 10 year term. The options granted during the six months ended June 30, 2023 were valued using the Black Scholes option pricing model using the following weighted-average assumptions: (i) expected term of 5.6 years; (ii) risk free interest rate of 3.55%; (iii) expected volatility of 128.6%; and (iv) dividend yield of 0.0%. The weighted-average grant date fair value of options issued by the Company during the three months ended June 30, 2023 was $11.72 per share.Stock options exercised during the three months ended June 30, 2023 and 2022, were 7,142 and 0, respectively. Stock options exercised during the six months ended June 30, 2023 and 2022, were 59,897 and 70,101, respectively. As of June 30, 2023, there were 1,709,150 options outstanding, of which 1,426,229 were vested and exercisable. As of December 31, 2022, there were 1,657,342 options outstanding, of which 1,310,667 were vested and exercisable.

1000000

2000000

281169

Stock-based compensation expense was as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.87%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.87%;margin:0pt;padding:0pt;">Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td></tr><tr><td style="vertical-align:bottom;width:52.13%;background:#cceeff;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 644,353</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 1,180,639</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 1,413,455</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 3,425,682</td></tr><tr><td style="vertical-align:bottom;width:52.13%;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 927,140</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 723,122</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,700,376</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,913,023</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,571,493</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,903,761</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,113,831</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,338,705</td></tr></table>

644353

1180639

1413455

3425682

927140

723122

1700376

1913023

1571493

1903761

3113831

5338705

111705

13.29

30000

P2Y

P10Y

P5Y7M6D

0.0355

1.286

0.000

11.72

7142

59897

70101

1709150

1426229

1657342

1310667

(9) Net Loss Per ShareThe following table sets forth the computation of basic and diluted net loss per share:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;margin:0pt;padding:0pt;">Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;background:#cceeff;margin:0pt;padding:0pt;">Numerator</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;">Net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (9,537,122)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,936,386)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (19,274,303)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (11,170,449)</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;background:#cceeff;margin:0pt;padding:0pt;">Denominator</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;">Weighted-average common shares outstanding, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 8,951,309</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 8,163,923</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 8,575,239</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 8,160,702</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;background:#cceeff;margin:0pt;padding:0pt;">Net loss per share, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (1.07)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (0.73)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> (2.25)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> (1.37)</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>The Company reported a net loss for the three and six months ended June 30, 2023 and 2022, therefore, the basic and diluted net loss per share were the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that were excluded from the computation of diluted weighted-average shares outstanding were as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;">Stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 1,709,150</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 1,627,941</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.69%;margin:0pt;padding:0pt;">Warrants</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 2,400</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 2,400</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td></tr></table>

The following table sets forth the computation of basic and diluted net loss per share:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;margin:0pt;padding:0pt;">Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;margin:0pt;padding:0pt;">Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;background:#cceeff;margin:0pt;padding:0pt;">Numerator</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;">Net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (9,537,122)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,936,386)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (19,274,303)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (11,170,449)</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;background:#cceeff;margin:0pt;padding:0pt;">Denominator</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;margin:0pt;padding:0pt;">Weighted-average common shares outstanding, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 8,951,309</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 8,163,923</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 8,575,239</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 8,160,702</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:46.61%;background:#cceeff;margin:0pt;padding:0pt;">Net loss per share, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (1.07)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (0.73)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> (2.25)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> (1.37)</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>

-9537122

-5936386

-19274303

-11170449

8951309

8163923

8575239

8160702

-1.07

-0.73

-2.25

-1.37

The Company reported a net loss for the three and six months ended June 30, 2023 and 2022, therefore, the basic and diluted net loss per share were the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that were excluded from the computation of diluted weighted-average shares outstanding were as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;">Stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 1,709,150</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 1,627,941</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.69%;margin:0pt;padding:0pt;">Warrants</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 2,400</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 2,400</td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"></td></tr></table>

1709150

1627941

2400

(10) Income TaxesThe Company’s income tax benefit (expense) was $0 for the three and six months ended June 30, 2023 and 2022. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss (“NOL”) that would have been recognized in the three and six months ended June 30, 2023 and 2022 was offset by changes in the valuation allowance.Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.As of June 30, 2023, and December 31, 2022, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.

(11) Restatement of Previously Issued Unaudited Condensed Financial StatementsAs disclosed in the Form 10-K filed with the SEC on March 31, 2023, during its preparation of its 2022 audited combined financial statements and notes thereto, the Company concluded that there were material research and development expenses and related balance sheet errors in its previously issued unaudited condensed financial statements for the three and six months ended June 30, 2022, primarily relating to the timing of payments for research and development expenses and recognition of expenses.The Company noted the following items were improperly expensed during the three and six months ended June 30, 2022: ● Payments, in the amount of $2,883,977 were improperly recorded in research and development expenses during the three months ended June 30, 2022. These amounts should have been recorded in prepaid expenses and other current assets as of June 30, 2022. Additionally, $102,232 was expensed during the three months ended June 30, 2022 related to the prior quarter restatements. These errors, including the errors from the three months ended March 31, 2022, in the accounting for research and development expenses resulted in a cumulative understatement of prepaid assets and other current assets of $3,441,895, as of June 30, 2022, and an overstatement operating expenses and net loss of $2,781,745 and $3,441,895 for the three and six months ended June 30, 2022, respectively. See Note 12 – Restatement of Previously Issued Unaudited Condensed Financial Statements, to the Financial Statements in the Form 10-K for additional information related to the restatements.In connection with the filing of this Quarterly Report on Form 10-Q, the Company has restated the accompanying interim Condensed Financial Statements for the quarter ended June 30, 2022 to correct for the impact of the misstatements. The applicable notes to the accompanying financial statements have also been corrected to reflect the impact of the restatement. Below, we have presented a reconciliation from the "As Reported" to the "As Restated" amounts for each of our interim Condensed Financial Statements as of and for the three and six months ended June 30, 2022. The amounts "As Reported" are from the "As Reported" amounts as disclosed in Note 12 – Restatement of Previously Issued Unaudited Condensed Financial Statements (Unaudited) in the Form 10-K.<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of June 30, 2022</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.1%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;">Restatement</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Reported</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Impacts</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Restated</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Current assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 35,974,251</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 35,974,251</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Prepaid expenses and other current assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 551,072</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 3,992,967</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Deferred clinical materials</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Total current assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,525,323</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39,967,218</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Total assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 36,525,323</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 39,967,218</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Liabilities and Stockholders' Equity</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Current liabilities:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Accounts payable</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 901,841</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 901,841</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Accrued expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 397,544</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 397,544</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Total current liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,299,385</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,299,385</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Total liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,299,385</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,299,385</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Commitments and contingencies (Note 7)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Stockholders' equity:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 816</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 816</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Additional paid-in capital</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 78,563,673</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 78,563,673</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Accumulated deficit</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (43,338,551)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (39,896,656)</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Total stockholders' equity</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,225,938</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 38,667,833</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Total liabilities and stockholders' equity</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 36,525,323</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 39,967,218</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended June 30, 2022</td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">As</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">Restatement</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">As</td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Reported</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Impacts</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Restated</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">Operating expenses:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 6,815,708</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,781,745)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 4,033,963</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,938,447</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,938,447</td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Total operating expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,754,155</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,781,745)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,972,410</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Operating loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,754,155)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,781,745</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,972,410)</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">Other income:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Interest income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 36,024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 36,024</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">Grant Income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Total other income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,024</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Loss before income taxes</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (8,718,131)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 2,781,745</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (5,936,386)</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">Income tax expense (benefit)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (8,718,131)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,781,745</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,936,386)</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">Basic and diluted loss per common share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.07)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.73)</td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Weighted average number of common shares outstanding, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,163,923</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,163,923</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Six Months Ended June 30, 2022</td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">Restatement</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Reported</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Impacts</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Restated</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">Operating expenses:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 9,625,499</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,441,895)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 6,183,604</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,042,518</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,042,518</td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Total operating expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,668,017</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,441,895)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,226,122</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Operating loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (14,668,017)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (11,226,122)</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">Other income:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Interest income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 55,673</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 55,673</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">Grant Income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Total other income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 55,673</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 55,673</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Loss before income taxes</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (14,612,344)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (11,170,449)</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">Income tax expense (benefit)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (14,612,344)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (11,170,449)</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">Basic and diluted loss per common share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.79)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.37)</td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Weighted average number of common shares outstanding, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,160,702</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,160,702</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:38.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Six Months Ended June 30, 2022</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;">Restatement</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Reported</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Impacts</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Restated</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Cash flows from operating activities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (14,612,344)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (11,170,449)</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Stock-based compensation expense</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 5,338,705</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 5,338,705</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Changes in operating assets and liabilities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Prepaid expenses and other current assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (235,608)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> (3,441,895)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (3,677,503)</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Accounts payable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 213,767</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 213,767</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Accrued expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (420,896)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (420,896)</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Net cash used in operating activities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,716,376)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,716,376)</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Cash flows from financing activities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Proceeds from exercise of stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,613</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,613</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Net cash used in financing activities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,613</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,613</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Net (decrease) increase in cash and cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> (9,711,763)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> (9,711,763)</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Cash and cash equivalents, beginning of period</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 45,686,014</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 45,686,014</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Cash and cash equivalents, end of period</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 35,974,251</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 35,974,251</td></tr></table>

2883977 102232 3441895

-2781745

-3441895

<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">As of June 30, 2022</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.1%;margin:0pt;padding:0pt;">(unaudited)</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;">Restatement</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Reported</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Impacts</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Restated</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Current assets:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Cash and cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 35,974,251</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 35,974,251</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Prepaid expenses and other current assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 551,072</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 3,992,967</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Deferred clinical materials</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Total current assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,525,323</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39,967,218</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Total assets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 36,525,323</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 39,967,218</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Liabilities and Stockholders' Equity</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Current liabilities:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Accounts payable</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 901,841</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 901,841</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Accrued expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 397,544</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 397,544</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Total current liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,299,385</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,299,385</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Total liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,299,385</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,299,385</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Commitments and contingencies (Note 7)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Stockholders' equity:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 816</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 816</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Additional paid-in capital</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 78,563,673</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 78,563,673</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Accumulated deficit</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (43,338,551)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (39,896,656)</td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;">Total stockholders' equity</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,225,938</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 38,667,833</td></tr><tr><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;">Total liabilities and stockholders' equity</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 36,525,323</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 39,967,218</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended June 30, 2022</td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">As</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">Restatement</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">As</td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Reported</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Impacts</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Restated</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">Operating expenses:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 6,815,708</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (2,781,745)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 4,033,963</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,938,447</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,938,447</td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Total operating expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,754,155</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,781,745)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,972,410</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Operating loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,754,155)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,781,745</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,972,410)</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">Other income:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Interest income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 36,024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 36,024</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">Grant Income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Total other income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,024</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Loss before income taxes</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (8,718,131)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 2,781,745</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (5,936,386)</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">Income tax expense (benefit)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (8,718,131)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,781,745</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,936,386)</td></tr><tr><td style="vertical-align:bottom;width:61.54%;background:#cceeff;margin:0pt;padding:0pt;">Basic and diluted loss per common share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.07)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.73)</td></tr><tr><td style="vertical-align:bottom;width:61.54%;margin:0pt;padding:0pt;">Weighted average number of common shares outstanding, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,163,923</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,163,923</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:38.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Six Months Ended June 30, 2022</td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">Restatement</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Reported</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Impacts</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Restated</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">Operating expenses:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Research and development</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 9,625,499</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> (3,441,895)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 6,183,604</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">General and administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,042,518</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,042,518</td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Total operating expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,668,017</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,441,895)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 11,226,122</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Operating loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (14,668,017)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (11,226,122)</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">Other income:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Interest income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 55,673</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 55,673</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">Grant Income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Total other income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 55,673</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 55,673</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Loss before income taxes</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (14,612,344)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (11,170,449)</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">Income tax expense (benefit)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (14,612,344)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (11,170,449)</td></tr><tr><td style="vertical-align:bottom;width:59.48%;background:#cceeff;margin:0pt;padding:0pt;">Basic and diluted loss per common share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.79)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.37)</td></tr><tr><td style="vertical-align:bottom;width:59.48%;margin:0pt;padding:0pt;">Weighted average number of common shares outstanding, basic and diluted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,160,702</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,160,702</td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:38.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Six Months Ended June 30, 2022</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;">Restatement</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;">As</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Reported</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Impacts</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Restated</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Cash flows from operating activities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (14,612,344)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> 3,441,895</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (11,170,449)</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Stock-based compensation expense</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 5,338,705</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 5,338,705</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Changes in operating assets and liabilities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Prepaid expenses and other current assets</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (235,608)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> (3,441,895)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (3,677,503)</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Accounts payable</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 213,767</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 213,767</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Accrued expenses</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (420,896)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (420,896)</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Net cash used in operating activities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,716,376)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,716,376)</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Cash flows from financing activities:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Proceeds from exercise of stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,613</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,613</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Net cash used in financing activities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,613</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,613</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Net (decrease) increase in cash and cash equivalents</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> (9,711,763)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> (9,711,763)</td></tr><tr><td style="vertical-align:bottom;width:59%;margin:0pt;padding:0pt;">Cash and cash equivalents, beginning of period</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 45,686,014</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 45,686,014</td></tr><tr><td style="vertical-align:bottom;width:59%;background:#cceeff;margin:0pt;padding:0pt;">Cash and cash equivalents, end of period</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 35,974,251</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 35,974,251</td></tr></table>

35974251

551072 3441895 3992967

36525323

3441895

39967218

36525323

3441895

39967218

901841

397544 397544

1299385

0.0001

2000000

0.0001

35000000

8163923

8100570

816

78563673

-43338551

3441895

-39896656

35225938

3441895

38667833

36525323

3441895

39967218

6815708

-2781745

4033963

1938447

8754155

-2781745

5972410

-8754155

2781745

-5972410

36024

-8718131

2781745

-5936386

-8718131

2781745

-5936386

-1.07

-0.73

8163923

9625499

-3441895

6183604

5042518

14668017

-3441895

11226122

-14668017

3441895

-11226122

55673

-14612344

3441895

-11170449

-14612344

3441895

-11170449

-1.79

-1.37

8160702

-14612344

3441895

-11170449

5338705

235608

3441895

3677503

213767

-420896

-9716376

4613

-9711763

45686014

35974251

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " )A0Y7B(RI-Z4! O&0 $P @ &A\@ I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 ,0 Q $X- !W] ! end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 84 153 1 false 22 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://annovisbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Balance Sheets Sheet http://annovisbio.com/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Balance Sheets (Parenthetical) Sheet http://annovisbio.com/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Statements of Operations and Comprehensive Loss Sheet http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00300 - Statement - Statements of Changes in Stockholders' Equity Sheet http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 00400 - Statement - Statements of Cash Flows Sheet http://annovisbio.com/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Nature of Business, Going Concern and Management's Plan Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlan Nature of Business, Going Concern and Management's Plan Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Fair Value Measurements Sheet http://annovisbio.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 10401 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 10501 - Disclosure - Accrued Expenses Sheet http://annovisbio.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 11 false false R12.htm 10601 - Disclosure - Commitments and Contingencies Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 10701 - Disclosure - Stockholders' Equity Sheet http://annovisbio.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 10801 - Disclosure - Stock-Based Compensation Sheet http://annovisbio.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 10901 - Disclosure - Net Loss Per Share Sheet http://annovisbio.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 15 false false R16.htm 11001 - Disclosure - Income Taxes Sheet http://annovisbio.com/role/DisclosureIncomeTaxes Income Taxes Notes 16 false false R17.htm 11101 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements Sheet http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements Restatement of Previously Issued Unaudited Condensed Financial Statements Notes 17 false false R18.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30303 - Disclosure - Fair Value Measurements (Tables) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://annovisbio.com/role/DisclosureFairValueMeasurements 19 false false R20.htm 30403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 20 false false R21.htm 30503 - Disclosure - Accrued Expenses (Tables) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://annovisbio.com/role/DisclosureAccruedExpenses 21 false false R22.htm 30803 - Disclosure - Stock-Based Compensation (Tables) Sheet http://annovisbio.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://annovisbio.com/role/DisclosureStockBasedCompensation 22 false false R23.htm 30903 - Disclosure - Net Loss Per Share (Tables) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://annovisbio.com/role/DisclosureNetLossPerShare 23 false false R24.htm 31103 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables) Sheet http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables) Tables http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements 24 false false R25.htm 40101 - Disclosure - Nature of Business, Going Concern and Management's Plan (Details) Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails Nature of Business, Going Concern and Management's Plan (Details) Details http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlan 25 false false R26.htm 40301 - Disclosure - Fair Value Measurements (Details) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://annovisbio.com/role/DisclosureFairValueMeasurementsTables 26 false false R27.htm 40401 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 27 false false R28.htm 40501 - Disclosure - Accrued Expenses (Details) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://annovisbio.com/role/DisclosureAccruedExpensesTables 28 false false R29.htm 40601 - Disclosure - Commitments and Contingencies - Leases (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails Commitments and Contingencies - Leases (Details) Details 29 false false R30.htm 40602 - Disclosure - Commitments and Contingencies - Employment Agreements (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails Commitments and Contingencies - Employment Agreements (Details) Details 30 false false R31.htm 40701 - Disclosure - Stockholders' Equity - Overview (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails Stockholders' Equity - Overview (Details) Details 31 false false R32.htm 40702 - Disclosure - Stockholders' Equity - Warrants (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails Stockholders' Equity - Warrants (Details) Details 32 false false R33.htm 40801 - Disclosure - Stock-Based Compensation (Details) Sheet http://annovisbio.com/role/DisclosureStockBasedCompensationDetails Stock-Based Compensation (Details) Details http://annovisbio.com/role/DisclosureStockBasedCompensationTables 33 false false R34.htm 40901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails Net Loss Per Share - Basic and diluted net loss per share (Details) Details 34 false false R35.htm 40902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails Net Loss Per Share - Potential shares excluded from calculation (Details) Details 35 false false R36.htm 41001 - Disclosure - Income Taxes (Details) Sheet http://annovisbio.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://annovisbio.com/role/DisclosureIncomeTaxes 36 false false R37.htm 41101 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Details) Sheet http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails Restatement of Previously Issued Unaudited Condensed Financial Statements (Details) Details http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables 37 false false R38.htm 41102 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details) Sheet http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details) Details http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables 38 false false R39.htm 41103 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details) Sheet http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details) Details http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables 39 false false R40.htm 41104 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details) Sheet http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details) Details 40 false false R41.htm 41105 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details) Sheet http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details) Details 41 false false All Reports Book All Reports anvs-20230630x10q.htm anvs-20230630.xsd anvs-20230630_cal.xml anvs-20230630_def.xml anvs-20230630_lab.xml anvs-20230630_pre.xml anvs-20230630xex31d1.htm anvs-20230630xex31d2.htm anvs-20230630xex32d1.htm anvs-20230630xex32d2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "anvs-20230630x10q.htm": { "axisCustom": 0, "axisStandard": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 436, "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 84, "dts": { "calculationLink": { "local": [ "anvs-20230630_cal.xml" ] }, "definitionLink": { "local": [ "anvs-20230630_def.xml" ] }, "inline": { "local": [ "anvs-20230630x10q.htm" ] }, "labelLink": { "local": [ "anvs-20230630_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20230630_pre.xml" ] }, "schema": { "local": [ "anvs-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 249, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 50, "http://xbrl.sec.gov/dei/2022": 7, "total": 57 }, "keyCustom": 15, "keyStandard": 138, "memberCustom": 7, "memberStandard": 14, "nsprefix": "anvs", "nsuri": "http://annovisbio.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://annovisbio.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Prepaid Expenses and Other Current Assets", "menuCat": "Notes", "order": "10", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Accrued Expenses", "menuCat": "Notes", "order": "11", "role": "http://annovisbio.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "12", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Stockholders' Equity", "menuCat": "Notes", "order": "13", "role": "http://annovisbio.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "14", "role": "http://annovisbio.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Net Loss Per Share", "menuCat": "Notes", "order": "15", "role": "http://annovisbio.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "16", "role": "http://annovisbio.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements", "menuCat": "Notes", "order": "17", "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements", "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "18", "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "19", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://annovisbio.com/role/StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": null }, "R20": { "firstAnchor": { "ancestors": [ "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "menuCat": "Tables", "order": "20", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Accrued Expenses (Tables)", "menuCat": "Tables", "order": "21", "role": "http://annovisbio.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "22", "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Net Loss Per Share (Tables)", "menuCat": "Tables", "order": "23", "role": "http://annovisbio.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)", "menuCat": "Tables", "order": "24", "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables", "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Nature of Business, Going Concern and Management's Plan (Details)", "menuCat": "Details", "order": "25", "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails", "shortName": "Nature of Business, Going Concern and Management's Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Fair Value Measurements (Details)", "menuCat": "Details", "order": "26", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "27", "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Accrued Expenses (Details)", "menuCat": "Details", "order": "28", "role": "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_NsimDsMQPUWIjVwgKEokcw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Commitments and Contingencies - Leases (Details)", "menuCat": "Details", "order": "29", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails", "shortName": "Commitments and Contingencies - Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_NsimDsMQPUWIjVwgKEokcw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_12_31_2022_OktWl38pkEuHULIFztR8SQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_G5NuVgu110KoGd8MzWaaXg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://annovisbio.com/role/StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_K9jCWmrYHkmazUpgFbXr_w", "decimals": "0", "first": true, "lang": null, "name": "anvs:MaximumAggregateSeverancePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Commitments and Contingencies - Employment Agreements (Details)", "menuCat": "Details", "order": "30", "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails", "shortName": "Commitments and Contingencies - Employment Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_srt_TitleOfIndividualAxis_srt_ExecutiveOfficerMember_K9jCWmrYHkmazUpgFbXr_w", "decimals": "0", "first": true, "lang": null, "name": "anvs:MaximumAggregateSeverancePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "INF", "first": true, "lang": null, "name": "anvs:NumberOfClassesOfStockDesignated", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_TEI62GJ82Uyt1X9Bd0hMsA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Stockholders' Equity - Overview (Details)", "menuCat": "Details", "order": "31", "role": "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "shortName": "Stockholders' Equity - Overview (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "INF", "first": true, "lang": null, "name": "anvs:NumberOfClassesOfStockDesignated", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_TEI62GJ82Uyt1X9Bd0hMsA", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_miDQI9lhAUe6j_5kcWelFA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Stockholders' Equity - Warrants (Details)", "menuCat": "Details", "order": "32", "role": "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails", "shortName": "Stockholders' Equity - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ClassOfWarrantOrRightOutstanding", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_12_31_2022_OktWl38pkEuHULIFztR8SQ", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_miDQI9lhAUe6j_5kcWelFA", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_NsimDsMQPUWIjVwgKEokcw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Stock-Based Compensation (Details)", "menuCat": "Details", "order": "33", "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_NsimDsMQPUWIjVwgKEokcw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_NsimDsMQPUWIjVwgKEokcw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)", "menuCat": "Details", "order": "34", "role": "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share - Basic and diluted net loss per share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ll7Vrx3AVUaLCk1f_FNRZw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_miDQI9lhAUe6j_5kcWelFA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)", "menuCat": "Details", "order": "35", "role": "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails", "shortName": "Net Loss Per Share - Potential shares excluded from calculation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ll7Vrx3AVUaLCk1f_FNRZw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_miDQI9lhAUe6j_5kcWelFA", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_NsimDsMQPUWIjVwgKEokcw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "36", "role": "http://annovisbio.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "0", "first": true, "lang": null, "name": "anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements (Details)", "menuCat": "Details", "order": "37", "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails", "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_T6wNv4un20WVqnnR6fwKZg", "decimals": "0", "lang": null, "name": "anvs:ResearchAndDevelopmentExpenseAggregateReclassification", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2023_k2YjJarL40yoD6JPhqeKEw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details)", "menuCat": "Details", "order": "38", "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements - Balance Sheets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_hGqFpYXKEU6AxAHahPlu5w", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_12_31_2022_OktWl38pkEuHULIFztR8SQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_G5NuVgu110KoGd8MzWaaXg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41103 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details)", "menuCat": "Details", "order": "39", "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails", "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements - Shares (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_NsimDsMQPUWIjVwgKEokcw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss", "shortName": "Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_4_1_2023_To_6_30_2023_NsimDsMQPUWIjVwgKEokcw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41104 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details)", "menuCat": "Details", "order": "40", "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember_bdraO9DDu0qNmnkSHpOyAA", "decimals": "0", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41105 - Disclosure - Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details)", "menuCat": "Details", "order": "41", "role": "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "shortName": "Restatement of Previously Issued Unaudited Condensed Financial Statements - Statements of Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_2xbTtt1Vgky_lz-1pHQlgw", "decimals": "0", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c_lzas4t00uK7geNidR1yA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Statements of Changes in Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity", "shortName": "Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VP2olAVyJEOX8OjnZtf2Cg", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://annovisbio.com/role/StatementStatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_RDSCHm_wSEy_bCq56yBzpA", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of Business, Going Concern and Management's Plan", "menuCat": "Notes", "order": "7", "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlan", "shortName": "Nature of Business, Going Concern and Management's Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "9", "role": "http://annovisbio.com/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "anvs-20230630x10q.htm", "contextRef": "Duration_1_1_2023_To_6_30_2023_8dXlTrKkDkqbskPylvwRig", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 22, "tag": { "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accrued Liabilities and Interest, and Employee-Related Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "verboseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "anvs_AdditionalExpenseForResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional expense recognized for research and development.", "label": "Additional Expense for Research and Development", "terseLabel": "Additional expense for research and development recognized in prepaid expenses and other current assets" } } }, "localname": "AdditionalExpenseForResearchAndDevelopment", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "anvs_AtMarketEquityOfferingCommonStockAuthorizedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The authorized value of common shares which may be sold under the terms of the At the Market (ATM) Equity Offering.", "label": "At the Market Equity Offering, Common Stock, Authorized Value", "verboseLabel": "Aggregate offering price" } } }, "localname": "AtMarketEquityOfferingCommonStockAuthorizedValue", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "monetaryItemType" }, "anvs_AtMarketEquityOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to an \"At the Market\" Equity Offering.", "label": "At the Market Equity Offering [Member]", "terseLabel": "At the Market Equity Offering" } } }, "localname": "AtMarketEquityOfferingMember", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "domainItemType" }, "anvs_BankOfAmericaAndThinkEquityLlcSalesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a sales agreement with Bank of America and Think Equity LLC.", "label": "Bank of America and Think Equity LLC Sales Agreement" } } }, "localname": "BankOfAmericaAndThinkEquityLlcSalesAgreementMember", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "domainItemType" }, "anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised.", "label": "Class of Warrant or Right, Number of Warrants Exercised", "terseLabel": "Number of warrants exercised" } } }, "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "anvs_CommonStockAndPreferredStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock And Preferred Stock, Shares Authorized", "terseLabel": "Number of common and preferred shares authorized" } } }, "localname": "CommonStockAndPreferredStockSharesAuthorized", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "sharesItemType" }, "anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "anvs_EarningsPerShareBasicAndDilutedDenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic and Diluted, Denominator [Abstract]", "terseLabel": "Denominator" } } }, "localname": "EarningsPerShareBasicAndDilutedDenominatorAbstract", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "anvs_EarningsPerShareBasicAndDilutedNumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic and Diluted, Numerator [Abstract]", "terseLabel": "Numerator" } } }, "localname": "EarningsPerShareBasicAndDilutedNumeratorAbstract", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "anvs_EquityIncentivePlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Company's 2019 Equity Incentive Plan.", "label": "2019 Plan" } } }, "localname": "EquityIncentivePlan2019Member", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "anvs_GrossProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The gross proceeds from the additional capital contribution to the entity through the issuance of common stock.", "label": "Gross Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds from issuance of common shares" } } }, "localname": "GrossProceedsFromIssuanceOfCommonStock", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "monetaryItemType" }, "anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for issuance costs associated with equity issuances.", "label": "Issuance Costs Associated with Equity Issuances [Policy Text Block]", "terseLabel": "Issuance Costs Associated with Equity Issuances" } } }, "localname": "IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "anvs_MaximumAggregateSeverancePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.", "label": "Maximum Aggregate Severance Payments", "terseLabel": "Maximum aggregate severance payments" } } }, "localname": "MaximumAggregateSeverancePayments", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "anvs_NatureOfBusinessAndLiquidityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Nature of Business and Liquidity [Abstract]", "terseLabel": "Nature of Business and Liquidity" } } }, "localname": "NatureOfBusinessAndLiquidityAbstract", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails" ], "xbrltype": "stringItemType" }, "anvs_NumberOfClassesOfStockDesignated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of classes of stock designated.", "label": "Number of classes of stock designated", "terseLabel": "Number of classes of stock designated" } } }, "localname": "NumberOfClassesOfStockDesignated", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "integerItemType" }, "anvs_NumberOfVotesForEachShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of vote for each share of common stock.", "label": "Number of Votes for Each Share of Common Stock", "terseLabel": "Number of vote for each share of common stock" } } }, "localname": "NumberOfVotesForEachShareOfCommonStock", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "integerItemType" }, "anvs_PercentageOfExercisePriceToShareOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of exercise price to the share offering price.", "label": "Percentage of Exercise Price to the Share Offering Price", "terseLabel": "Percentage of exercise price to the share offering price" } } }, "localname": "PercentageOfExercisePriceToShareOfferingPrice", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "percentItemType" }, "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.", "label": "Prepaid Expense, Security Deposits, and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "anvs_PrepaidResearchAndDevelopmentExpenseCurrent": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Research and Development Expense, Current", "terseLabel": "Prepaid clinical trial expenses" } } }, "localname": "PrepaidResearchAndDevelopmentExpenseCurrent", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "anvs_PreviousPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to previous plans.", "label": "Previous Plans" } } }, "localname": "PreviousPlansMember", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "anvs_QuarterlyInstallmentVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to vesting in quarterly installments", "label": "Service-based vesting, quarterly installments" } } }, "localname": "QuarterlyInstallmentVestingMember", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "anvs_ResearchAndDevelopmentExpenseAggregateReclassification": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount reclassified to prepaid expenses and other current assets.", "label": "Research and Development Expense, Aggregate Reclassification", "terseLabel": "Aggregate amount reclassified from research and development expense to prepaid expenses and other current assets" } } }, "localname": "ResearchAndDevelopmentExpenseAggregateReclassification", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Immediate vesting of awards under share-based payment arrangement.", "label": "Immediate Vesting" } } }, "localname": "ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "anvs_UnderwritersWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Underwriters warrants.", "label": "Underwriters warrants" } } }, "localname": "UnderwritersWarrantsMember", "nsuri": "http://annovisbio.com/20230630", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "label": "Executive Officers" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r161", "r162", "r163", "r164", "r195", "r202", "r231", "r232", "r233", "r293", "r294", "r300", "r312", "r313", "r322", "r326", "r333", "r362", "r366", "r406", "r407", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r161", "r162", "r163", "r164", "r195", "r202", "r231", "r232", "r233", "r293", "r294", "r300", "r312", "r313", "r322", "r326", "r333", "r362", "r366", "r406", "r407", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r80", "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r114", "r115", "r116", "r117", "r118", "r119", "r130", "r155", "r156", "r254", "r270", "r271", "r272", "r273", "r287", "r288", "r289", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r80", "r104", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r114", "r115", "r116", "r117", "r118", "r119", "r130", "r155", "r156", "r254", "r270", "r271", "r272", "r273", "r287", "r288", "r289", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": { "auth_ref": [ "r109", "r110", "r111", "r114", "r115", "r117", "r118" ], "lang": { "en-us": { "role": { "label": "Restatement Impacts" } } }, "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r80", "r104", "r106", "r107", "r108", "r109", "r110", "r118", "r130", "r254", "r270", "r271", "r272", "r287", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r351", "r352", "r353", "r354", "r355", "r359", "r360", "r396", "r400", "r401" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "terseLabel": "As Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r357", "r402" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r312", "r313", "r405", "r407", "r410" ], "lang": { "en-us": { "role": { "label": "Weighted average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r8", "r332" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional and clinical fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r3", "r332" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r239", "r240", "r241", "r348", "r349", "r350", "r395" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net Loss Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r67", "r72", "r85", "r101", "r141", "r144", "r148", "r153", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r263", "r267", "r280", "r332", "r364", "r365", "r403" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r82", "r89", "r101", "r153", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r263", "r267", "r280", "r332", "r364", "r365", "r403" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "terseLabel": "Total current assets", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r206", "r207", "r208", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "verboseLabel": "Basis of Presentation of Interim Unaudited Financial Statements" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r25", "r84", "r314" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents, Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r21", "r25", "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r21", "r65" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "terseLabel": "Net (decrease) increase in cash and cash equivalents", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents, Carrying Value" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Stockholders' Equity" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r52", "r56" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of warrants issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r52", "r56" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r13", "r69", "r75" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r40", "r159", "r160", "r311", "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r348", "r349", "r395" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Number of common shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r2", "r44" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r2", "r332" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - $0.0001 par value, 35,000,000 shares authorized and 8,163,923 and 8,100,570 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively", "verboseLabel": "Common stock - $0.0001 par value, 70,000,000 and 35,000,000 shares authorized and 9,012,273 and 8,163,923 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangements [Abstract]", "terseLabel": "Employment Agreements" } } }, "localname": "DeferredCompensationArrangementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r205", "r236", "r237", "r238", "r243", "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r96", "r109", "r110", "r112", "r113", "r114", "r120", "r122", "r124", "r125", "r126", "r130", "r272", "r273", "r296", "r298", "r316" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic loss per common share", "verboseLabel": "Net loss per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r96", "r109", "r110", "r112", "r113", "r114", "r122", "r124", "r125", "r126", "r130", "r272", "r273", "r296", "r298", "r316" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted loss per common share", "verboseLabel": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Net (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r127", "r128", "r129", "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r44", "r79", "r93", "r94", "r95", "r104", "r105", "r106", "r108", "r115", "r118", "r132", "r154", "r192", "r239", "r240", "r241", "r253", "r254", "r271", "r281", "r282", "r283", "r284", "r285", "r286", "r289", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting error correction.", "label": "Error Correction [Text Block]", "terseLabel": "Restatement of Previously Issued Unaudited Condensed Financial Statements" } } }, "localname": "ErrorCorrectionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Restatement of Previously Issued Unaudited Condensed Financial Statements" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r174", "r196", "r197", "r198", "r199", "r200", "r201", "r275", "r290", "r291", "r292", "r320", "r321", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r274", "r275", "r276", "r277", "r279" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r174", "r196", "r201", "r275", "r290", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r174", "r196", "r197", "r198", "r199", "r200", "r201", "r290", "r291", "r292", "r320", "r321", "r323", "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r63", "r64" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r18" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r15", "r66", "r70", "r77", "r141", "r143", "r147", "r149", "r297", "r318" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income taxes", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Operations and Comprehensive Loss" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r102", "r247", "r248", "r251", "r255", "r257", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Accrued interest or penalties" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r103", "r117", "r118", "r140", "r246", "r256", "r258", "r299" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r92", "r244", "r245", "r248", "r249", "r250", "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r23" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r23" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r23" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Changes in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income, net", "verboseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Leases" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r10", "r101", "r153", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r264", "r267", "r268", "r280", "r317", "r364", "r403", "r404" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r7", "r68", "r74", "r332", "r347", "r358", "r398" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "terseLabel": "Total liabilities and stockholders' equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r12", "r83", "r101", "r153", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r264", "r267", "r268", "r280", "r332", "r364", "r403", "r404" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "terseLabel": "Total current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r98" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "terseLabel": "Net cash provided by financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r21", "r22", "r24" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r16", "r24", "r71", "r76", "r81", "r90", "r91", "r95", "r101", "r107", "r109", "r110", "r112", "r113", "r117", "r118", "r123", "r141", "r143", "r147", "r149", "r153", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r273", "r280", "r318", "r364" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net and comprehensive loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r19" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Total other income", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses", "verboseLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r141", "r143", "r147", "r149", "r318" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating loss", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rental expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business, Going Concern and Management's Plan" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r61" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business, Going Concern and Management's Plans" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r344", "r361" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r1", "r175" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Number of preferred shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r1", "r175" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsSharesDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r1", "r332" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r315", "r319", "r361" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "verboseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restatement of Previously Issued Unaudited Condensed Financial Statements" } } }, "localname": "PriorPeriodAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r20" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r20", "r59" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r81", "r90", "r91", "r97", "r101", "r107", "r117", "r118", "r141", "r143", "r147", "r149", "r153", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r262", "r265", "r266", "r273", "r280", "r297", "r318", "r330", "r331", "r345", "r364" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r60", "r78", "r411" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r38", "r39", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r4", "r51", "r73", "r305", "r310", "r332" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r79", "r104", "r105", "r106", "r108", "r115", "r118", "r154", "r239", "r240", "r241", "r253", "r254", "r271", "r301", "r303" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r138", "r139", "r142", "r145", "r146", "r150", "r151", "r152", "r193", "r194", "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of shares excluded from the computation of diluted weighted-average shares outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r54", "r55" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r109", "r110", "r111", "r114", "r115", "r117", "r118", "r130" ], "lang": { "en-us": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r29", "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "terseLabel": "Schedule of Restatement of Previously Issued Unaudited Condensed Financial Statements" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r203", "r204", "r206", "r207", "r208", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r41", "r42", "r43", "r45", "r46", "r47", "r48", "r49", "r50", "r51", "r86", "r87", "r88", "r133", "r175", "r176", "r177", "r179", "r183", "r188", "r190", "r322", "r341", "r346" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r343" ], "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposits and other" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r23" ], "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfCashFlowsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options, vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r206", "r207", "r208", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r234" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r209", "r228", "r229", "r230", "r231", "r234", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Term of award (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r28", "r99" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r14", "r44", "r79", "r93", "r94", "r95", "r104", "r105", "r106", "r108", "r115", "r118", "r132", "r154", "r192", "r239", "r240", "r241", "r253", "r254", "r271", "r281", "r282", "r283", "r284", "r285", "r286", "r289", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Changes in Stockholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r104", "r105", "r106", "r132", "r295" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r1", "r2", "r44", "r51" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs, shares", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessGoingConcernAndManagementSPlanDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r1", "r2", "r44", "r51", "r215" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "verboseLabel": "Exercise of stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r1", "r2", "r44", "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r14", "r44", "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r2", "r5", "r6", "r37", "r332", "r347", "r358", "r398" ], "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity", "verboseLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsBalanceSheetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r53", "r100", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r189", "r192", "r269" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityOverviewDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "terseLabel": "Liability for uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r34", "r35", "r36", "r134", "r135", "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r121", "r126" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding, diluted", "verboseLabel": "Weighted-average common shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r120", "r126" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding, basic", "verboseLabel": "Weighted-average common shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/DisclosureRestatementOfPreviouslyIssuedUnauditedCondensedFinancialStatementsStatementsOfOperationsDetails", "http://annovisbio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r334": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r335": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r336": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r337": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r338": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r339": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 60 0001558370-23-014884-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-014884-xbrl.zip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�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end